Ekso Bionics Holdings Inc

Financial Health of Ekso Bionics Holdings Inc

Comparing to competitors in the Medical Instruments & Supplies industry

Industry Rankings

Ekso Bionics Holdings Inc
Buy, Hold or Sell?

Should you buy, hold or sell Ekso Bionics Holdings Inc?

I guess you are interested in Ekso Bionics Holdings Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

Let's analyse Ekso Bionics Holdings Inc

Let's start. I'm going to help you getting a better view of Ekso Bionics Holdings Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Show more...

Company's Financial Health
A deep dive into the books. How are the numbers doing? Is Ekso Bionics Holdings Inc even making a profit? Is the company skyrocketing? Or is it sinking like the Titanic. The trend is your friend.
Market Valuation
Finally, you now have an insight of how Ekso Bionics Holdings Inc is doing in the market. If the company is worth buying. The latest step is to find out how other investors value Ekso Bionics Holdings Inc. The closing price on 2022-12-02 was $1.22 per share. Is the company over- or underpriced?
Key Performance Indicators
A total overlook on how the company is doing. Based on the (trends in) the key performance indicators.

Ekso Bionics Holdings Inc Daily Candlestick Chart

Summary

Financial Health

Profitability Details

	Compared to previous year	Compared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.

Operating Efficiency Details

	Compared to previous year	Compared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.

Liquidity Details

	Compared to previous year	Compared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.

Solvency Details

	Compared to previous year	Compared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

1.1. Profitability of Ekso Bionics Holdings Inc.

1.1. Profitability

1.1.1. Net Profit Margin

Measures how much net profit Ekso Bionics Holdings Inc earns for each $1 of revenue.

Above 10% is considered healthy but always compare Ekso Bionics Holdings Inc to the Medical Instruments & Supplies industry mean.
A Net Profit Margin of -129.3% means that $-1.29 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Ekso Bionics Holdings Inc:

The MRQ is -129.3%. The company is making a huge loss. -2
The TTM is -116.4%. The company is making a huge loss. -2

Trends

Current period		Compared to		+/-
MRQ	-129.3%	TTM	-116.4%	-12.9%
TTM	-116.4%	YOY	-122.6%	+6.2%
TTM	-116.4%	5Y	-162.7%	+46.3%
5Y	-162.7%	10Y	-255.8%	+93.1%

Compared to industry (Medical Instruments & Supplies)

Period	Company	Industry (mean)	+/-
MRQ	-129.3%	7.5%	-136.8%
TTM	-116.4%	7.3%	-123.7%
YOY	-122.6%	8.7%	-131.3%
5Y	-162.7%	6.8%	-169.5%
10Y	-255.8%	7.0%	-262.8%

Measures how much net profit Ekso Bionics Holdings Inc earns for each $1 of revenue.

Revenue is the amount of profit Ekso Bionics Holdings Inc generates before taxes and all other costs. For example, when you buy a cup of coffee it will cost you $3. The company does not earn $3 in profit but also has to pay various costs and taxes to create that cup of coffee. Let's assume the cost of creating a cup of coffee is $1.5.

The $3 you pay for a cup of coffee is called revenue.
The $1.5 that’s left over when all costs to create that cup of coffee (including taxes) are deduced from the revenue is called net profit.

The net profit margin looks at how much net profit Ekso Bionics Holdings Inc earns for each $1 in revenue.

How to use net profit margin

Higher profit margin is better (more profit).
Above 10% is considered healthy but always compare Ekso Bionics Holdings Inc to the Medical Instruments & Supplies industry mean.
Can be used to compare companies within the Medical Instruments & Supplies industry.

You typically want a high profit margin. This means that for each $1 in sales, Ekso Bionics Holdings Inc makes more profit. This shows the investor how efficiently Ekso Bionics Holdings Inc is operating in general and compared to other companies in the same industry. Ekso Bionics Holdings Inc operates in the Medical Instruments & Supplies industry.

Why do investors use net profit margin in their analysis

It helps investors to determine the efficiency of Ekso Bionics Holdings Inc. If profit margins remain low (compared to the Medical Instruments & Supplies industry mean) and there are no improvements to make in production costs or other areas that might be a warning sign. If profit margins are high that means the company has low overhead costs and is efficiently using its resources to generate profit.

The three steps every investor should look at:

What is the current net profit margin?
The current most recent quarter (MRQ) Net Profit Margin of Ekso Bionics Holdings Inc is -1.29. This means that Ekso Bionics Holdings Inc earned $-1.29 for each $1 in revenue in the most recent quarter.
How does it compare to the industry?
The mean MRQ Net Profit Margin of the Medical Instruments & Supplies industry is 7.5%.
What is the trend?
The trend is important because it shows you how Ekso Bionics Holdings Inc is performing over time. The most recent quarter might be important if Ekso Bionics Holdings Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Ekso Bionics Holdings Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare Ekso Bionics Holdings Inc with other companies in the same industry (Medical Instruments & Supplies).
Net profit margin should rise over the years.
Can be influenced when Ekso Bionics Holdings Inc sells assets (profit will increase while costs remain the same).
It won’t show what part of Ekso Bionics Holdings Inc is doing great or needs improvement (it only looks at total revenue and total net income).

How to calculate net profit margin

Net profit margin = net income / total revenue * 100%

Real example of Ekso Bionics Holdings Inc

You need the following data to determine net profit margin:

Income statement from the period you want to calculate (for example, MRQ or TTM).

Net income MRQ Ekso Bionics Holdings Inc = -4,304
Total revenue MRQ Ekso Bionics Holdings Inc = 3,329
$-4,304 / $3,329 = -1.29 or -129.3%

Higher is better

The higher the net profit margin, the more efficient the company is generating income. This helps investors to determine how the company is managing money. The net profit margin is an important indicator when diving into the financial health of a company. Overall, you want to see the net profit margin rising over the years. That means the company improved their production and made it more efficient (if possible).

You can use the net profit margin to compare companies within the same industry. If there are two companies where one is much bigger but the smaller one has a higher net profit margin, that means the smaller company is more efficiently using operational costs.

Important: Profit margins can be very different between industries. Companies with assembly lines or transports are much more prone to see shifting in prices for fuel, ingredients and maintenance compared to companies that only provide services. You should never compare net profit margin between different industries.

1.1.2. Return on Assets

Shows how efficient Ekso Bionics Holdings Inc is using its assets to generate profit.

Above 5% is considered healthy but always compare Ekso Bionics Holdings Inc to the Medical Instruments & Supplies industry mean.
-10.9% Return on Assets means that Ekso Bionics Holdings Inc generated $-0.11 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Ekso Bionics Holdings Inc:

The MRQ is -10.9%. Using its assets, the company is very inefficient in making profit. -2
The TTM is -8.6%. Using its assets, the company is very inefficient in making profit. -2

Trends

Current period		Compared to		+/-
MRQ	-10.9%	TTM	-8.6%	-2.3%
TTM	-8.6%	YOY	-8.0%	-0.6%
TTM	-8.6%	5Y	-15.8%	+7.2%
5Y	-15.8%	10Y	-220.6%	+204.8%

Compared to industry (Medical Instruments & Supplies)

Period	Company	Industry (mean)	+/-
MRQ	-10.9%	1.5%	-12.4%
TTM	-8.6%	1.4%	-10.0%
YOY	-8.0%	1.5%	-9.5%
5Y	-15.8%	1.2%	-17.0%
10Y	-220.6%	1.3%	-221.9%

Shows how efficient Ekso Bionics Holdings Inc is using its assets to generate profit.

For a farm, a tractor is considered an asset. The tractor helps ploughing the land making it possible to plant and harvest crops. But the tractor might be old and needing maintenance all the time reducing its efficiency. Return on assets indicates how effectively the farm is using the tractor (and other assets that help the core business) to plough the land.

How to use return on assets

Higher is better.
Above 5% is considered healthy but always compare Ekso Bionics Holdings Inc to the Medical Instruments & Supplies industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use return on assets in their analysis

Shows the investor how effectively Ekso Bionics Holdings Inc is using its resources to generate profit. If the return on assets (-10.9%) from Ekso Bionics Holdings Inc are higher than the Medical Instruments & Supplies mean (1.5%) that means Ekso Bionics Holdings Inc is using its resources better than their competitors. If not, that means their competitors are more efficient in using their resources to generate profit.

An investor should always look at:

What is the current return on assets?
The current most recent quarter (MRQ) Return on Assets of Ekso Bionics Holdings Inc is -10.9%. This means the company generated $-0.11 for each $1 in assets.
How does it compare to the industry?
The mean MRQ Return on Assets of the Medical Instruments & Supplies industry is 1.5%.
What is the trend?
The trend is important because it shows you how Ekso Bionics Holdings Inc is performing over time. The most recent quarter might be important if Ekso Bionics Holdings Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Ekso Bionics Holdings Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
If a company has many assets changing over time, it’s better to calculate the average assets instead of the total assets.

How to calculate return on assets

Return on assets = net income / total assets * 100%

Real example Ekso Bionics Holdings Inc

You need the following data to determine return on assets (ROA):

Income statement
Balance sheet

Net income MRQ (income statement) from Ekso Bionics Holdings Inc = -4,304
Total assets MRQ (balance sheet) from Ekso Bionics Holdings Inc = 39,311
-4,304 / 39,311 = -0.11 or -10.9%

ROA is an important ratio as it will tell you how effectively Ekso Bionics Holdings Inc is using its resources to generate profits. Example:

Bob and Kristin both sell ice cream in the summer. They both have an ice cream truck. The truck Bob owes cost him $20.000 and the truck Kristin owes cost her $1500. Over the summer, Bob earned $2000 and Kristin earned $200. To calculate the return on assets:

Bob: $2000 / $20.000 * 100% = 10%
Kristin: $200 / $1500 * 100% = 13.3%

This tells you Bob’s company is more valuable but Kristin's company is more efficient. Be aware that total assets can change over time. A transportation business will buy and sell trucks or planes all the time. Before using return on assets as a guideline, you have to know what the exact assets are. For a company that has many assets changing over time, it’s better to calculate the average assets instead of the total assets.

1.1.3. Return on Equity

Shows how efficient Ekso Bionics Holdings Inc is using its investors money to generate profit.

Above 15%-20% is considered healthy but always compare Ekso Bionics Holdings Inc to the Medical Instruments & Supplies industry mean.
-15.0% Return on Equity means Ekso Bionics Holdings Inc generated $-0.15 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Ekso Bionics Holdings Inc:

The MRQ is -15.0%. Using its investors money, the company is very inefficient in making profit. -2
The TTM is -11.5%. Using its investors money, the company is very inefficient in making profit. -2

Trends

Current period		Compared to		+/-
MRQ	-15.0%	TTM	-11.5%	-3.6%
TTM	-11.5%	YOY	-26.7%	+15.2%
TTM	-11.5%	5Y	-44.3%	+32.8%
5Y	-44.3%	10Y	-55.0%	+10.7%

Compared to industry (Medical Instruments & Supplies)

Period	Company	Industry (mean)	+/-
MRQ	-15.0%	2.4%	-17.4%
TTM	-11.5%	2.6%	-14.1%
YOY	-26.7%	2.9%	-29.6%
5Y	-44.3%	2.3%	-46.6%
10Y	-55.0%	2.4%	-57.4%

Shows how efficient Ekso Bionics Holdings Inc is using its investors money to generate profit.

A publicly traded company (any company that issues shares to the public) is owned by its shareholders. Return on equity calculates the amount of profit for every $1 the shareholders invested.

How to use return on equity

Higher is better.
Above 15%-20% is considered healthy but always compare Ekso Bionics Holdings Inc to the Medical Instruments & Supplies industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use return on equity in their analysis

To find out the owners/management's attitude toward their company. You typically want the owners/management to invest in the company and focus on generating profit. If not enough profit is generated (compared to the Medical Instruments & Supplies industry mean), the company might not be investing their money efficiently.

The three steps every investor should look at:

What is the current return on equity?
The current most recent quarter (MRQ) Return on Equity of Ekso Bionics Holdings Inc is -15.0%. This means Ekso Bionics Holdings Inc generated $-0.15 for each $1 the owners (shareholders) invested.
How does it compare to the industry?
The mean MRQ Return on Equity of the Medical Instruments & Supplies industry is 2.4%.
What is the trend?
The trend is important because it shows you how Ekso Bionics Holdings Inc is performing over time. The most recent quarter might be important if Ekso Bionics Holdings Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Ekso Bionics Holdings Inc up to 10 years back (depending if Ekso Bionics Holdings Inc existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Does not include intangible assets (non physical assets like licences, computer software, etc.).
Stockholders equity and shareholders equity refer to the same thing.
Liabilities should not be more than three times return on equity.

How to calculate return on equity

Return on equity = net profit / shareholders equity * 100%

Real example of Ekso Bionics Holdings Inc

You need the following data to determine ROE:

Income statement
Balance sheet
Net profit MRQ (income statement) Ekso Bionics Holdings Inc = -4,304
Shareholders equity (balance sheet) MRQ Ekso Bionics Holdings Inc = 28,614
-4,304 / 28,614 = -0.15 or -15.0%

A negative shareholder equity is a warning sign. It means the company has more liabilities than assets. It might also mean that the owners did not invest enough money or they are taking money out of the business.

1.2. Operating Efficiency of Ekso Bionics Holdings Inc.

1.2. Operating Efficiency

1.2.1. Operating Margin

Measures how efficient Ekso Bionics Holdings Inc is operating .

Measures how much profit Ekso Bionics Holdings Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
Above 15% is considered healthy but always compare Ekso Bionics Holdings Inc to the Medical Instruments & Supplies industry mean.
An Operating Margin of -128.3% means the company generated $-1.28 for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Ekso Bionics Holdings Inc:

The MRQ is -128.3%. The company is operating very inefficient. -2
The TTM is -115.4%. The company is operating very inefficient. -2

Trends

Current period		Compared to		+/-
MRQ	-128.3%	TTM	-115.4%	-12.9%
TTM	-115.4%	YOY	-121.5%	+6.0%
TTM	-115.4%	5Y	-159.5%	+44.1%
5Y	-159.5%	10Y	-252.8%	+93.2%

Compared to industry (Medical Instruments & Supplies)

Period	Company	Industry (mean)	+/-
MRQ	-128.3%	10.1%	-138.4%
TTM	-115.4%	9.8%	-125.2%
YOY	-121.5%	10.8%	-132.3%
5Y	-159.5%	7.9%	-167.4%
10Y	-252.8%	7.2%	-260.0%

Measures how efficient Ekso Bionics Holdings Inc is operating .

The more effecient a company creates products or provides services, the more profit it generates.

How to use operating margin

Higher is better
Above 15% is considered healthy but always compare Ekso Bionics Holdings Inc to the Medical Instruments & Supplies industry mean.
Can be very different between industries
Can be used to compare companies

Why do investors use operating margin in their analysis

To determine how much profit Ekso Bionics Holdings Inc is making from it’s core business.

The three steps every investor should look at:

What is the current net profit margin?
The current most recent quarter (MRQ) Operating Margin of Ekso Bionics Holdings Inc is -128.3%. This means that Ekso Bionics Holdings Inc earned $-1.28 for each $1 in revenue in the most recent quarter.
How does it compare to the industry?
The mean MRQ Operating Margin of the Medical Instruments & Supplies industry is 10.1%.
What is the trend?
The trend is important because it shows you how Ekso Bionics Holdings Inc is performing over time. The most recent quarter might be important if Ekso Bionics Holdings Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Ekso Bionics Holdings Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry
Can be calculated in different ways

How to calculate operating margin

Operating margin = operating earnings / total revenue

Real example of Ekso Bionics Holdings Inc

You need the following data to determine operating margin:

Income statement
Operating earnings MRQ Ekso Bionics Holdings Inc = -3,654
Total revenue MRQ Ekso Bionics Holdings Inc = 3,329
$-3,654 / $3,329 = -1.28 or -128.3%

Operating margin is used to calculate how much profit a company makes after variable costs of production but before paying interest and taxes. Some variable costs examples are wages, raw materials, packaging, and transaction fees. The amount of variable costs is different for each company and industry. In general, a higher operating margin is better as this implicates that a company is running efficiently.

For investors, a higher operating margin is a good sign. Although you should always look at operating margin in the long term. If operating margin is fluctuating over the years this might be a sign that things are not running efficiently enough. It’s a way to check how much profit a company is making from its core business.

Operation earnings can be calculated in multiple ways:

Operation earnings = EBIT - non operating income + non operating expense
Operation earnings = Gross profit - operating expense - depreciation and amortisation
Operation earnings = Total revenue - COGS (costs of goods sold) - indirect costs

1.2.2. Operating Ratio

Measures how efficient Ekso Bionics Holdings Inc is keeping operating costs low.

Below 1 is considered healthy (always compare to Medical Instruments & Supplies industry mean).
An Operation Ratio of 2.10 means that the operating costs are $2.10 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Ekso Bionics Holdings Inc:

The MRQ is 2.098. The company is inefficient in keeping operating costs low. -1
The TTM is 2.199. The company is inefficient in keeping operating costs low. -1

Trends

Current period		Compared to		+/-
MRQ	2.098	TTM	2.199	-0.102
TTM	2.199	YOY	2.351	-0.151
TTM	2.199	5Y	2.671	-0.471
5Y	2.671	10Y	3.032	-0.361

Compared to industry (Medical Instruments & Supplies)

Period	Company	Industry (mean)	+/-
MRQ	2.098	1.172	+0.926
TTM	2.199	1.094	+1.105
YOY	2.351	0.990	+1.361
5Y	2.671	1.046	+1.625
10Y	3.032	1.006	+2.026

Measures how efficient Ekso Bionics Holdings Inc is keeping operating costs low.

If the operating ratio is below 1 that means the company is making money. The lower the operating ratio, the more efficient the company.

How to use operating ratio

Lower is better.
Below 1 is considered healthy but always compare Ekso Bionics Holdings Inc to the Medical Instruments & Supplies industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use operating ratio in their analysis

Shows if costs of creating products and or services is increasing or decreasing. The lower the operating ratio, the more efficient the company is creating products and services.

The three steps every investor should look at:

What is the current Operatin ratio?
The current most recent quarter (MRQ) Operating Ratio of Ekso Bionics Holdings Inc is 209.8%. This means that Ekso Bionics Holdings Inc earned $2.10 for each $1 in net sales in the most recent quarter.
How does it compare to the industry?
The mean MRQ Operating Ratio of the Medical Instruments & Supplies industry is 1.17.
What is the trend?
The trend is important because it shows you how Ekso Bionics Holdings Inc is performing over time. The most recent quarter might be important if Ekso Bionics Holdings Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Ekso Bionics Holdings Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
You need COGS to calculate operating ratio which is not always shown in the income statement.
Does not consider debt.

How to calculate operating ratio

Operating ratio = Operating expenses + COGS \ Net sales

Real life example Ekso Bionics Holdings Inc

You need the following data to determine operating ratio:

Income statement

COGS is not always specified on the income statement. If so you can use the following calculation:

(cost of revenue + total operating expenses) \ total revenue
(1,643 +5,340) \ 3,329 = 2.10

The operating ratio measures the efficiency of a company at keeping low costs while generating profits from sales. It compares the total operating expenses to the net amount of sales. The total operating expenses exists of:

COGS (materials, labour, rent of facility, repairs)
Operating expenses (legal fees, marketing, wages, rent, maintenance/repairs)

Operating expenses are all the costs the company makes that are not directly tied to the production of the service or product. Where COGS are costs that are directly tied to the production of a product or service.

Do note that COGS is not always available in the income statement. Some companies include COGS in the operating expenses while others list COGS separately. To make it even more confusing, COGS is also known as “costs of sales” and costs of sales is the same as costs of revenue.

The operating ratio tells you how efficient the company is creating its products or services while keeping prices low. In this case, a lower ratio is better. Higher or rising operating ratios might tell you that costs are rising while sales are not improving or staying the same.

1.3. Liquidity of Ekso Bionics Holdings Inc.

1.3. Liquidity

1.3.1. Current Ratio

Measures if Ekso Bionics Holdings Inc is able to pay off Short-term Debt.

Above 1.5 is considered healthy (always compare to Medical Instruments & Supplies industry mean).
A Current Ratio of 4.68 means the company has $4.68 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Ekso Bionics Holdings Inc:

The MRQ is 4.677. The company is very able to pay all its short-term debts. +2
The TTM is 6.758. The company is very able to pay all its short-term debts. +2

Trends

Current period		Compared to		+/-
MRQ	4.677	TTM	6.758	-2.081
TTM	6.758	YOY	8.573	-1.815
TTM	6.758	5Y	4.545	+2.213
5Y	4.545	10Y	3.529	+1.016

Compared to industry (Medical Instruments & Supplies)

Period	Company	Industry (mean)	+/-
MRQ	4.677	2.529	+2.148
TTM	6.758	2.586	+4.172
YOY	8.573	2.402	+6.171
5Y	4.545	2.490	+2.055
10Y	3.529	2.359	+1.170

Measures if Ekso Bionics Holdings Inc is able to pay off Short-term Debt.

How to use current ratio

Higher is better
Above 1.5 is considered healthy (always compare to Medical Instruments & Supplies industry mean).
Can be very different between industries
Can be used to compare companies

Why do investors use current ratio in their analysis

Shows if the company can pay of short term debts if needed. A company that can't pay off it's short term debts might get in trouble if they have to pay off their short term debts for whatever reason. For example, markets can change due to global events like covid-19 or the war in Ukraine versus Russia. Because debts are always taken based on future income, it might become troublesome for Ekso Bionics Holdings Inc if something happens in the market that will cause sales to plummet.

The three steps every investor should look at:

What is the current current Ratio?
The current most recent quarter (MRQ) Current Ratio of Ekso Bionics Holdings Inc is 4.68. This means Ekso Bionics Holdings Inc has $4.68 in assets for each $1 in short-term debts.
How does it compare to the industry?
The mean MRQ Current Ratio of the Medical Instruments & Supplies industry is 2.53.
What is the trend?
The trend is important because it shows you how Ekso Bionics Holdings Inc is performing over time. The most recent quarter might be important if Ekso Bionics Holdings Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Ekso Bionics Holdings Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Might be deluded.
Not all assets can always be quickly sold.
Can be manipulated by increasing or decreasing the assets and/or liabilities.

How to calculate current ratio

Current ratio = current assets \ current liabilities

Real life example Ekso Bionics Holdings Inc

You need the following data to determine operating ratio:

Balance sheet
Current ratio = current assets \ current liabilities
36,754 \ 7,858) = 4.68

The current ratio measures if Ekso Bionics Holdings Inc is able to pay short-term debts (obligations). Short term in this context means all debt obligations that are about to expire within one year. The current ratio incorporates current liabilities and current assets. Current assets are all the assets a company has that are expected to be consumed or sold within standard business operations. You can find the current assets in the balance sheet. They consist of:

Inventory
Accounts receivable
Marketable securities
Prepaid expenses
Cash
Cash equivalents
liquid assets

The current liabilities are short term obligations that are due within one year. These consist of:

Short term debts
Dividends
Income taxes
Short-term debts
Accounts payable
Interest payments

The result shows an investor if Ekso Bionics Holdings Inc is able to pay all its short-term debts if they were due all at once. When the result of the above formula is below 1, then Ekso Bionics Holdings Inc does not have enough capital after selling all its assets to pay all short-term debts. If the ratio drops far below 1 that might indicate Ekso Bionics Holdings Inc is or will be in financial trouble anytime soon.

Although this gives an investor some clues, the current ratio may also be deluded. Because owning assets does not mean the company can easily sell them. Also, Accounts receivable may be quite old (they will probably never pay) which deludes the current ratio. As with all ratios, you should only compare them between the same industries and companies.

1.3.2. Quick Ratio

Measures if Ekso Bionics Holdings Inc is able to pay off Short-term Debt but only using the most liquid assets.

Above 1 is considered healthy but always compare Ekso Bionics Holdings Inc to the Medical Instruments & Supplies industry mean.
A Quick Ratio of 4.15 means the company can pay off $4.15 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Ekso Bionics Holdings Inc:

The MRQ is 4.146. The company is very able to pay all its short-term debts with the most liquid assets. +2
The TTM is 6.164. The company is very able to pay all its short-term debts with the most liquid assets. +2

Trends

Current period		Compared to		+/-
MRQ	4.146	TTM	6.164	-2.018
TTM	6.164	YOY	8.073	-1.909
TTM	6.164	5Y	4.083	+2.080
5Y	4.083	10Y	3.079	+1.004

Compared to industry (Medical Instruments & Supplies)

Period	Company	Industry (mean)	+/-
MRQ	4.146	1.102	+3.044
TTM	6.164	1.064	+5.100
YOY	8.073	1.119	+6.954
5Y	4.083	1.094	+2.989
10Y	3.079	1.026	+2.053

Measures if Ekso Bionics Holdings Inc is able to pay off Short-term Debt but only using the most liquid assets.

How to use quick ratio

Higher is better.
Above 1 is considered healthy but always compare Ekso Bionics Holdings Inc to the Medical Instruments & Supplies industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use quick ratio in their analysis

Shows how fast Ekso Bionics Holdings Inc can pay off its short term debts. This shows if Ekso Bionics Holdings Inc can survive emergencies due to market changes or other reasons.

The three steps every investor should look at:

What is the current Quick Ratio?
The current most recent quarter (MRQ) quickRatio of Ekso Bionics Holdings Inc is 4.15. This means that Ekso Bionics Holdings Inc can pay off $4.15 for each $1 in debt (using most liquid assets).
How does it compare to the industry?
The mean MRQ Quick Ratio of the Medical Instruments & Supplies industry is 1.10.
What is the trend?
The trend is important because it shows you how Ekso Bionics Holdings Inc is performing over time. The most recent quarter might be important if Ekso Bionics Holdings Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Ekso Bionics Holdings Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Incorporates only most liquid assets.

How to calculate quick ratio

Quick ratio = cash and equivalents + marketable securities + accounts receivable / current liabilities

Real life example Ekso Bionics Holdings Inc

You need the following data to determine operating ratio:

Balance sheet
Quick ratio = cash and short-term investments + short-term investments + netReceivables / total current liabilities
MRQ quick ratio Ekso Bionics Holdings Inc: (29,180 + +3,398) / 7,858 = 4.15

The quick ratio measures the same thing as the current ratio, only it uses the most liquid assets a company has. Meaning, the assets that can be sold for cash the easiest and fastest.

As the quick ratio only incorporates the most liquid assets, you should also check the current ratio which also includes less liquid assets. But they may be harder to sell.

1.4. Solvency of Ekso Bionics Holdings Inc.

1.3. Liquidity

1.4.1. Debt to Asset Ratio

Measures how much % of Ekso Bionics Holdings Inc assets are financed with debt.

Below 1 (100%) is considered healthy but always compare Ekso Bionics Holdings Inc to Medical Instruments & Supplies industry mean.
A Debt to Asset Ratio of 0.27 means that Ekso Bionics Holdings Inc assets are financed with 27.2% credit (debt) and the remaining percentage (100% - 27.2%) is financed by its owners/shareholders.

Let's take a look of the Debt to Asset Ratio trends of Ekso Bionics Holdings Inc:

The MRQ is 0.272. The company is very able to pay all its debts by selling its assets. +2
The TTM is 0.244. The company is very able to pay all its debts by selling its assets. +2

Trends

Current period		Compared to		+/-
MRQ	0.272	TTM	0.244	+0.028
TTM	0.244	YOY	0.383	-0.139
TTM	0.244	5Y	0.551	-0.307
5Y	0.551	10Y	6.338	-5.787

Compared to industry (Medical Instruments & Supplies)

Period	Company	Industry (mean)	+/-
MRQ	0.272	0.347	-0.075
TTM	0.244	0.341	-0.097
YOY	0.383	0.368	+0.015
5Y	0.551	0.376	+0.175
10Y	6.338	0.372	+5.966

Measures how much % of Ekso Bionics Holdings Inc assets are financed with debt.

When there are more debts than assets, that means creditors have a larger stake Ekso Bionics Holdings Inc than its shareholders.

How to use debt to asset ratio

Lower is better.
below 1 (100%) is considered healthy but always compare Ekso Bionics Holdings Inc to Medical Instruments & Supplies industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use the debt to asset ratio in their analysis

It shows how much debt the company used to finance its assets. If a company is almost entirely financed with debt that means the company might get into serious trouble when emergencies arise like a raise in interest.

The three steps every investor should look at:

What is the current debt to asset ratio?
The current most recent quarter (MRQ) Debt to Asset Ratio of Ekso Bionics Holdings Inc is 0.27. This means means that Ekso Bionics Holdings Inc is financed with 27.2% credit and the remaining percentage is financed by it's owners (shareholders).
How does it compare to the industry?
The mean MRQ Current Ratio of the Medical Instruments & Supplies industry is 252.9%.
What is the trend?
The trend is important because it shows you how Ekso Bionics Holdings Inc is performing over time. The most recent quarter might be important if Ekso Bionics Holdings Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Ekso Bionics Holdings Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry
Some companies can have higher debt to assets ratio's (for example, banks).
Debt to asset ratio should improve over the years.
If the debt to asset ratio is above 1, look at the industry mean and find out why Ekso Bionics Holdings Inc has so much debt.

How to calculate debt to asset ratio

Debt to asset ratio = total debt \ total assets

Real life example Ekso Bionics Holdings Inc

You need the following data to determine debt to asset ratio:

Balance sheet
Debt to asset ratio = total debt \ total assets
10,697 \ 39,311 = 27.2% or 0.27.

The debt to total assets ratio shows if the company is owned by creditors or shareholders. Or in other words, the total debt in relation to the total amount of assets. It shows how much debt the company used to finance its assets.

1.4.2. Debt to Equity Ratio

Measures if Ekso Bionics Holdings Inc is able to pay off its debts by using shareholders equity.

Below 2 is considered healthy but always compare Ekso Bionics Holdings Inc to the Medical Instruments & Supplies industry mean.
A Debt to Equity ratio of 37.4% means that company has $0.37 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Ekso Bionics Holdings Inc:

The MRQ is 0.374. The company is very able to pay all its debts with equity. +2
The TTM is 0.323. The company is very able to pay all its debts with equity. +2

Trends

Current period		Compared to		+/-
MRQ	0.374	TTM	0.323	+0.051
TTM	0.323	YOY	1.161	-0.838
TTM	0.323	5Y	1.704	-1.381
5Y	1.704	10Y	1.735	-0.031

Compared to industry (Medical Instruments & Supplies)

Period	Company	Industry (mean)	+/-
MRQ	0.374	0.517	-0.143
TTM	0.323	0.520	-0.197
YOY	1.161	0.591	+0.570
5Y	1.704	0.628	+1.076
10Y	1.735	0.632	+1.103

Measures if Ekso Bionics Holdings Inc is able to pay off its debts by using shareholders equity.

How to use debt to equity ratio

Lower is better.
Below 2 is considered healthy (always use industry average).
Can be very different between industries.
Can be used to compare companies.

Why do investors use the debt to shareholders equity ratio in their analysis

It shows how much debt the company uses to finance their operations. Shareholders equity is whats left over when you subtract total liabilities from total assets. It's another way to meassure how much of Ekso Bionics Holdings Inc is financed with debt or own resources.

The three steps every investor should look at:

What is the current debt to equity ratio?
The current most recent quarter (MRQ) quickRatio of Ekso Bionics Holdings Inc is 0.37. This means that Ekso Bionics Holdings Inc can pay off $0.37 for each $1 in debt.
How does it compare to the industry?
The mean MRQ Quick Ratio of the Medical Instruments & Supplies industry is 0.52.
What is the trend?
The trend is important because it shows you how Ekso Bionics Holdings Inc is performing over time. The most recent quarter might be important if Ekso Bionics Holdings Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Ekso Bionics Holdings Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Not all debt is equally risky (for example, short term risk is less risky).

How to calculate debt to equity ratio

Debt to equity ratio = total debt \ shareholders equity.

Real life example Ekso Bionics Holdings Inc

You need the following data to determine equity ratio:

Balance sheet
Debt to equity ratio = total debt \ shareholders equity
10,697 \ 28,614 = 0.37 or 37.4%

Debt to equity measures the total debt versus the total shareholders equity. While the total debts to total assets ratio uses total assets, the debt to equity ratio looks at the total equity of shareholders. Where equity of shareholders are:

Common shares.
Preferred shares.
Retained earnings.

You can find the shareholders' equity in the balance sheet. A ratio between 0,5 and 1,5 is preferred. If the ratio is above 1.5, that would indicate creditors have significantly more stake (debt) in the company than the shareholders. In other words, the company is using a lot of debt to finance their operations.

Not all debt is equally risky. Meaning you can adjust the ratio by including or excluding certain amounts of debt. Short term debts are less risky because they have to be paid back within one year anyway. It’s much easier to plan one year ahead versus five or ten years.

2. Market Valuation of Ekso Bionics Holdings Inc

2. Earnings Per Share

2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Ekso Bionics Holdings Inc generates.

Above 15 is considered overpriced but always compare Ekso Bionics Holdings Inc to the Medical Instruments & Supplies industry mean.
A PE ratio of -4.74 means the investor is paying $-4.74 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Ekso Bionics Holdings Inc:

The EOD is -3.705. Company is losing money. -2
The MRQ is -4.738. Company is losing money. -2
The TTM is -8.040. Company is losing money. -2

Trends

Current period		Compared to		+/-
EOD	-3.705	MRQ	-4.738	+1.033
MRQ	-4.738	TTM	-8.040	+3.303
TTM	-8.040	YOY	-32.251	+24.210
TTM	-8.040	5Y	-7.578	-0.463
5Y	-7.578	10Y	-4.758	-2.819

Compared to industry (Medical Instruments & Supplies)

Period	Company	Industry (mean)	+/-
EOD	-3.705	59.546	-63.251
MRQ	-4.738	61.746	-66.484
TTM	-8.040	85.285	-93.325
YOY	-32.251	98.197	-130.448
5Y	-7.578	57.263	-64.841
10Y	-4.758	53.213	-57.971

Measures how much money you pay for each share for every $1 in earnings Ekso Bionics Holdings Inc generates.

Indicates if the company’s shares are under or overvalued.

How to use PE ratio

Above 15 is considered overpriced but is hard to determine. Always compare Ekso Bionics Holdings Inc to the Medical Instruments & Supplies industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use PE ratio in their analysis

The PE ratio tells investors the current sentiment in the market for that company. As with every stock, the stock price never shows the real valuation of a company but rather how the market thinks how much the stock is worth.

In other words, the current stock price also incorporates any future earnings or business opportunities in the future. The best example is the stock market crash in 2000. The PE ratio for any internet based company was going through the roof. Only based on the general assumption the internet and all associated businesses would thrive in the future. But this was based on nothing. A business still needs a good product or service to be able to survive. Instead, every investor bought any stock which did something related to the internet. Result: huge market crash.

Many investors were willing to pay premium prices and that was causing the PE ratio to rise. A high PE ratio is a warning sign that investors might be overvaluing a stock based on future earnings.

The three steps every investor should look at:

What is the current PE Ratio?
The current most recent quarter (MRQ) PE Ratio of Ekso Bionics Holdings Inc is -4.74. This means the investor is paying $-4.74 for every $1 in earnings.
How does it compare to the industry?
The mean MRQ Quick Ratio of the Medical Instruments & Supplies industry is 61.75.
What is the trend?
The trend is important because it shows you how Ekso Bionics Holdings Inc is performing over time. The most recent quarter might be important if Ekso Bionics Holdings Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Ekso Bionics Holdings Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Some industries might have very high or very low PE ratios in general.
PE ratios can be high for several years, it does not mean a sudden collapse is imminent.
Earnings growth is not included in the PE ratio.

How to calculate PE ratio

PE ratio = market value per share \ earnings per share

Real life example Ekso Bionics Holdings Inc

You need the following data to determine the PE ratio:

Balance sheet
Income statement

The PE ratio is a very commonly used ratio to determine the value of a company by comparing the current stock price relative to its earnings per share (EPS). Before we can calculate the PE ratio we need to know the EPS. EPS is calculated as follows:

EPS = (net profit - preferred dividends) \ end of period outstanding shares*
Net profit = revenue - expenses
-4,304 \ 13,071 = EPS
PE ratio MRQ = -4.74

* The net profit minus preferred dividends can be found in the incomestatement as netIncomeApplicableToCommonShares.

The PE value helps investors to determine if the current stock price is under or overvalued. It also projects future growth.

In general, a higher PE ratio means that investors predict higher future growth. If the PE ratio is too high, then investors expect way too much future growth the company can never fulfil. This is most likely to happen in faster moving companies like tech companies or automobile companies like Tesla. These are hot and booming markets where investors expect much future growth driven by new technology (electric cars). When looking at the current MRQ (most recent quarter) PE ratio of Tesla ( jan. 2021) it's about 247 while the average in the industry is only 6. That might be a clue that Tesla is trading for way too high prices compared to their current assets and is more based on future growth.

2.2. Price Earnings to Growth Ratio

Measures the predicted future growth of Ekso Bionics Holdings Inc.

Lower is better.
A PEG ratio of 1 means the market price of the stock and the expected future earnings are on par.

Let's take a look of the Price Earnings to Growth Ratio trends of Ekso Bionics Holdings Inc:

The MRQ is 15.496. Seems overpriced? -1
The TTM is 15.494. Seems overpriced? -1

Trends

Current period		Compared to		+/-
MRQ	15.496	TTM	15.494	+0.002
TTM	15.494	YOY	-48.067	+63.562
TTM	15.494	5Y	-1.547	+17.042
5Y	-1.547	10Y	0.327	-1.874

Compared to industry (Medical Instruments & Supplies)

Period	Company	Industry (mean)	+/-
MRQ	15.496	-0.016	+15.512
TTM	15.494	-0.191	+15.685
YOY	-48.067	0.014	-48.081
5Y	-1.547	0.044	-1.591
10Y	0.327	0.101	+0.226

PEG Ratio	Meaning
0.5	You can buy the stock cheap based on future growth
1	You pay a fair price based on future growth
2	The stock is overpriced based on future growth

2. Book Value per Share

2.3. Price to Book Ratio

Measures if the stock price of Ekso Bionics Holdings Inc is to cheap or to expensive compared to its book value.

At or below 1 is considered healthy (always compare to Medical Instruments & Supplies industry mean).
A PB ratio of 0.71 means the investor is paying $0.71 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Ekso Bionics Holdings Inc:

The EOD is 0.557. Very good. +2
The MRQ is 0.713. Very good. +2
The TTM is 0.860. Very good. +2

Trends

Current period		Compared to		+/-
EOD	0.557	MRQ	0.713	-0.155
MRQ	0.713	TTM	0.860	-0.148
TTM	0.860	YOY	5.825	-4.964
TTM	0.860	5Y	-191.880	+192.741
5Y	-191.880	10Y	-95.077	-96.803

Compared to industry (Medical Instruments & Supplies)

Period	Company	Industry (mean)	+/-
EOD	0.557	2.751	-2.194
MRQ	0.713	2.850	-2.137
TTM	0.860	3.702	-2.842
YOY	5.825	4.453	+1.372
5Y	-191.880	3.597	-195.477
10Y	-95.077	3.186	-98.263

2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Ekso Bionics Holdings Inc.

3.1. Institutions holding Ekso Bionics Holdings Inc

Institutions are holding 15.96% of the shares of Ekso Bionics Holdings Inc.

Date	Name	Total Shares	Total Assets	Current Shares	Change	%
2022-06-30	Vanguard Group Inc	3.3829	0	440683	0	0
2022-06-30	Essex Investment Management Company, LLC	1.2869	0.0448	167645	0	0
2022-06-30	Sabby Management LLC	1.0913	0.1599	142165	-256635	-64.3518
2022-06-30	Geode Capital Management, LLC	0.83	0	108122	0	0
2022-06-30	Renaissance Technologies Corp	0.3424	0.0001	44606	27006	153.4432
2022-06-30	Susquehanna International Group, LLP	0.2273	0	29610	18336	162.6397
2022-06-30	Compagnie Lombard, Odier SCA	0.1919	0.001	25000	0	0
2022-06-30	Citadel Advisors Llc	0.1913	0	24920	24920	0
2022-06-30	State Street Corporation	0.1779	0	23180	1500	6.9188
2022-09-30	Strategic Wealth Designers	0.1721	0.0101	22419	-7982	-26.2557
2022-06-30	Northern Trust Corp	0.1567	0	20414	-3184	-13.4927
2022-06-30	TWO SIGMA SECURITIES, LLC	0.1513	0.0012	19707	19707	0
2022-06-30	Virtu Financial LLC	0.0868	0.0016	11306	11306	0
2022-06-30	JANE STREET GROUP, LLC	0.0865	0	11262	11262	0
2022-06-30	Advisor Group Holdings, Inc.	0.076	0	9895	0	0
2022-09-30	Hanson Mcclain Inc	0.0463	0.0001	6029	0	0
2022-06-30	UBS Group AG	0.0462	0	6024	6024	0
2022-06-30	Tower Research Capital LLC	0.0271	0.0001	3524	3524	0
2022-06-30	SIMPLEX TRADING, LLC	0.0257	0	3353	2777	482.1181
2022-06-30	Group One Trading, LP	0.0143	0	1869	-1919	-50.66
Total		8.6109	0.2189	1121733	-143358	-12.8%

3.2. Funds holding Ekso Bionics Holdings Inc

Date	Name	Total Shares	Total Assets	Current Shares	Change	%
2022-09-30	AZ Fd1 AZ Allc Tr A-AZ C	4.606	0.0501	600000	0	0
2022-09-30	Vanguard Instl Ttl Stck Mkt Idx Tr	1.8684	0	243385	100	0.0411
2022-10-31	Vanguard Total Stock Mkt Idx Inv	1.8684	0	243385	0	0
2022-10-31	Vanguard Extended Market Index Investor	1.3754	0.0004	179165	0	0
2022-09-30	Fidelity® Extended Market Index	0.5387	0.0004	70168	0	0
2022-09-30	Azimut Trend	0.2687	0.038	35000	0	0
2022-10-31	iShares Core S&P Total US Stock Mkt ETF	0.1338	0.0001	17430	0	0
2022-06-30	Essex Inv Mgt Micro Cap Growth	0.1209	0.3916	15751	0	0
2022-09-30	Fidelity® Total Market Index	0.1139	0	14838	0	0
2022-10-31	Vanguard Instl Ttl Stk Mkt Idx InstlPls	0.1081	0.0001	14085	0	0
2022-09-30	NT Ext Equity Mkt Idx Fd - NL	0.0931	0.0004	12133	0	0
2022-09-30	Fidelity® Series Total Market Index	0.0904	0	11780	0	0
2022-09-30	NT Ext Equity Mkt Idx Fd - DC - NL - T2	0.0751	0.0004	9784	131	1.3571
2022-09-30	AZ Fd 1 Equity Escalator B-AZ EUR Dis	0.0538	0.0013	7005	-36	-0.5113
2022-09-30	NT Ext Equity Mkt Idx Fd - L	0.0534	0.0003	6962	0	0
2022-09-30	Northern Trust Extended Eq Market Idx	0.0534	0.0003	6962	0	0
2022-06-30	BlackRock Extended Mkt Composite	0.0529	0.0001	6892	6892	0
2022-06-30	Trecento Robotique ISR I EUR	0.0513	0.2771	6681	257	4.0006
2022-09-30	BlackRock Extended Equity Market K	0.0467	0.0001	6085	-56	-0.9119
2022-09-30	Fidelity® NASDAQ Composite Index®	0.0449	0.0001	5843	0	0
Total		11.6173	0.7608	1513334	+7288	+0.5%

3.3. Insider Transactions

Insiders are holding 8.024% of the shares of Ekso Bionics Holdings Inc.

Date	Owner	Type	Amount	Price	Post Transaction Amount
2022-10-24	Steven Sherman	SELL	5921	1.29	698230
2022-09-22	Steven Sherman	SELL	6043	1.75	688551
2022-08-22	Steven Sherman	SELL	5572	2.2	678995
2022-08-03	Jerome Wong	SELL	1675	1.8	102192
2022-07-25	Steven Sherman	SELL	5662	1.75	668968
2022-07-18	Jerome Wong	SELL	98	1.71	103867
2022-06-30	Scott G Davis	SELL	4997	1.72	368818
2022-06-22	Steven Sherman	SELL	5330	1.74	659031
2022-06-15	Steven Sherman	SELL	6911	1.9	648762
2022-05-24	Steven Sherman	SELL	6597	1.76	637408
2022-04-28	Steven Sherman	SELL	6862	2.41	628406
2022-04-20	Scott G Davis	SELL	4043	2.62	73815
2022-03-24	Steven Sherman	SELL	6389	2.94
2022-03-22	Jason C Jones	SELL	3265	2.82
2022-03-22	John Glenn	SELL	3462	2.82
2022-03-15	Steven Sherman	SELL	5965	2.6
2018-05-23	Steven Sherman	BUY	200000	1.51
2017-11-22	Russ Angold	SELL	50000	3.51
2017-09-14	Amy Mcbride Wendell	BUY	16264	1.23	16264
2017-09-08	Thomas Looby	BUY	15000	1.13	20315

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Ekso Bionics Holdings Inc compared to the Most Recent Quarter (MRQ).

	End of day	+/-	Most Recent Quarter	Trailing 12 Months	+/-	Year-Over-Year	+/-	5 Year	+/-	10 Year	+/-
Book Value Change Per Share	-	-	-0.247	-0.202	-18%	0.588	-142%	-0.004	-98%	0.055	-550%
Book Value Growth	-	-	-0.109	-0.081	-25%	-0.013	-88%	-9.490	+8617%	-4.817	+4325%
Book Value Per Share	-	-	2.189	2.513	-13%	2.391	-8%	1.322	+66%	0.715	+206%
Book Value Per Share Growth	-	-	-0.113	-0.082	-27%	-0.013	-89%	-9.490	+8325%	-4.817	+4177%
Current Ratio	-	-	4.677	6.758	-31%	8.573	-45%	4.545	+3%	3.529	+33%
Debt To Asset Ratio	-	-	0.272	0.244	+12%	0.383	-29%	0.551	-51%	6.338	-96%
Debt To Equity Ratio	-	-	0.374	0.323	+16%	1.161	-68%	1.704	-78%	1.735	-78%
Dividend Per Share	-	-	-	-	0%	-	0%	-	0%	-	0%
Eps	-	-	-0.329	-0.283	-14%	-0.209	-37%	-0.158	-52%	-0.426	+29%
Eps Growth	-	-	-0.306	-0.113	-63%	0.000	-100%	0.837	-137%	0.781	-139%
Gross Profit Margin	-	-	1.405	1.522	-8%	1.800	-22%	0.850	+65%	1.059	+33%
Net Profit Margin	-	-	-1.293	-1.164	-10%	-1.226	-5%	-1.627	+26%	-2.558	+98%
Operating Margin	-	-	-1.283	-1.154	-10%	-1.215	-5%	-1.595	+24%	-2.528	+97%
Operating Ratio	-	-	2.098	2.199	-5%	2.351	-11%	2.671	-21%	3.032	-31%
Pb Ratio	0.557	-28%	0.713	0.860	-17%	5.825	-88%	-191.880	+27026%	-95.077	+13442%
Pe Ratio	-3.705	+22%	-4.738	-8.040	+70%	-32.251	+581%	-7.578	+60%	-4.758	+0%
Peg Ratio	-	-	15.496	15.494	+0%	-48.067	+410%	-1.547	+110%	0.327	+4639%
Price Per Share	1.220	-28%	1.560	2.188	-29%	5.605	-72%	3.047	-49%	2.347	-34%
Price To Total Gains Ratio	-4.948	+22%	-6.326	-11.844	+87%	-39.411	+523%	-10.743	+70%	-8.233	+30%
Profit Growth	-	-	-30.809	-11.328	-63%	-0.005	-100%	104.373	-130%	53.341	-158%
Quick Ratio	-	-	4.146	6.164	-33%	8.073	-49%	4.083	+2%	3.079	+35%
Return On Assets	-	-	-0.109	-0.086	-21%	-0.080	-27%	-0.158	+45%	-2.206	+1915%
Return On Equity	-	-	-0.150	-0.115	-24%	-0.267	+78%	-0.443	+195%	-0.550	+266%
Revenue Growth	-	-	-0.041	-0.029	-28%	-0.014	-67%	-0.022	-46%	-0.071	+74%
Total Gains Per Share	-	-	-0.247	-0.202	-18%	0.588	-142%	-0.004	-98%	0.055	-550%
Total Gains Per Share Growth	-	-	-0.453	-0.068	-85%	-11.184	+2369%	-2.367	+423%	-1.275	+181%
Usd Book Value	-	-	28614000.000	32762000.000	-13%	31141750.000	-8%	17227150.000	+66%	9321591.300	+207%
Usd Book Value Change Per Share	-	-	-0.247	-0.202	-18%	0.588	-142%	-0.004	-98%	0.055	-550%
Usd Book Value Per Share	-	-	2.189	2.513	-13%	2.391	-8%	1.322	+66%	0.715	+206%
Usd Dividend Per Share	-	-	-	-	0%	-	0%	-	0%	-	0%
Usd Eps	-	-	-0.329	-0.283	-14%	-0.209	-37%	-0.158	-52%	-0.426	+29%
Usd Price Per Share	1.220	-28%	1.560	2.188	-29%	5.605	-72%	3.047	-49%	2.347	-34%
Usd Profit	-	-	-4304000.000	-3691250.000	-14%	-2719250.000	-37%	-4279750.000	-1%	-4564652.025	+6%
Usd Revenue	-	-	3329000.000	3359250.000	-1%	2356000.000	+41%	2859550.000	+16%	2340050.000	+42%
Usd Total Gains Per Share	-	-	-0.247	-0.202	-18%	0.588	-142%	-0.004	-98%	0.055	-550%
	EOD	+3 -2	MRQ	TTM	+4 -29	YOY	+9 -24	5Y	+19 -14	10Y	+23 -10

4.2. Fundamental Score

Let's check the fundamental score of Ekso Bionics Holdings Inc based on Penke's default stock scanner.

Penke's Stock Scanner

Indicator	Condition		Value
Price to Earnings Ratio (EOD)	Between	0-15	-3.705
Price to Book Ratio (EOD)	Between	0-1	0.557
Net Profit Margin (MRQ)	Greater than	0	-1.293
Operating Margin (MRQ)	Greater than	0	-1.283
Quick Ratio (MRQ)	Greater than	1	4.146
Current Ratio (MRQ)	Greater than	1	4.677
Debt to Asset Ratio (MRQ)	Less than	1	0.272
Debt to Equity Ratio (MRQ)	Less than	1	0.374
Return on Equity (MRQ)	Greater than	0.15	-0.150
Return on Assets (MRQ)	Greater than	0.05	-0.109
Total			5/10 (50.0%)

Create your own Stock Scanner

Investing is personal. The best investors buy stocks based on their own analysis. Create your personal Stock Scanner with the key performance indicators that are important to you.
Create your own Stock Scanner

4.3. Technical Score

Let's check the technical score of Ekso Bionics Holdings Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

Indicator	Condition		Value
Open	Greater than	Close	1.240
Total			1/1 (100.0%)

Create your own Symbol Scanner

Trading is personal. The best traders buy and sell based on their own technical analysis. Create your personal Symbol Scanner with the technical indicators that are important to you.
Create your own Symbol Scanner

Latest Balance Sheet

Balance Sheet of 2022-09-30. Currency in USD. All numbers in thousands.

Summary

Total Assets	39,311
Total Liabilities	10,697
Total Stockholder Equity	28,614

	As reported
Total Liabilities	10,697
Total Stockholder Equity	+ 28,614
Total Assets	= 39,311

Assets

Total Assets	39,311
Total Current Assets	36,754
Long-term Assets	36,754

Total Current Assets

Total Current Assets (as reported)	36,754
Cash And Cash Equivalents	29,180
Net Receivables	3,398
Inventory	3,508
Other Current Assets	668
Total Current Assets (calculated)	36,754
+/-	0

Long-term Assets

Long-term Assets (as reported)	2,557
Property Plant Equipment	2,333
Other Assets	224
Long-term Assets (calculated)	2,557
+/-	0

Liabilities & Shareholders' Equity

Total Current Liabilities	7,858
Long-term Liabilities	2,839
Total Stockholder Equity	28,614

Total Current Liabilities

Total Current Liabilities (as reported)	7,858
Short-term Debt	244
Short Long Term Debt	1,996
Accounts payable	2,387
Other Current Liabilities	4,168
Total Current Liabilities (calculated)	8,795
+/-	937

Long-term Liabilities

Long-term Liabilities (as reported)	2,839
Capital Lease Obligations Min Short Term Debt	1,167
Other Liabilities	1,672
Long-term Liabilities (calculated)	2,839
+/-	0

Total Stockholder Equity

Total Stockholder Equity (as reported)	28,614
Common Stock	13
Retained Earnings	-220,769
Accumulated Other Comprehensive Income	1,486
Other Stockholders Equity	247,884
Total Stockholder Equity (calculated)	28,614
+/-	0

Other

Capital Stock	13
Cash and Short Term Investments	29,180
Common Stock Shares Outstanding	13,071
Current Deferred Revenue	1,059
Liabilities and Stockholders Equity	39,311
Net Debt	-27,769
Net Invested Capital	30,610
Net Tangible Assets	28,614
Net Working Capital	28,896
Short Long Term Debt Total	1,411

Balance Sheet

Currency in USD. All numbers in thousands.

Trend

2022-09-30

2022-06-30

2022-03-31

2021-12-31

2021-09-30

2021-06-30

2021-03-31

2020-12-31

2020-09-30

2020-06-30

2020-03-31

2019-12-31

2019-09-30

2019-06-30

2019-03-31

2018-12-31

2018-09-30

2018-06-30

2018-03-31

2017-12-31

2017-09-30

2017-06-30

2017-03-31

2016-12-31

2016-09-30

2016-06-30

2016-03-31

2015-12-31

2015-09-30

2015-06-30

2015-03-31

2014-12-31

2014-09-30

2014-06-30

2014-03-31

2013-12-31

2013-09-30

2013-06-30

2013-03-31

2012-12-31

2012-09-30

2012-06-30

> Total Assets

5
13
30
29
29
0
0
21,801
18,598
15,418
33,474
30,033
26,906
22,126
32,198
22,551
13,575
21,621
24,425
16,895
18,932
43,405
37,988
30,959
23,208
22,423
17,655
20,860
25,583
20,292
21,915
16,944
22,349
23,486
20,597
56,504
52,973
50,733
49,166
44,242
40,520
39,311

39,311

40,520

44,242

49,166

50,733

52,973

56,504

20,597

23,486

22,349

16,944

21,915

20,292

25,583

20,860

17,655

22,423

23,208

30,959

37,988

43,405

18,932

16,895

24,425

21,621

13,575

22,551

32,198

22,126

26,906

30,033

33,474

15,418

18,598

21,801

> Total Current Assets

5
13
30
29
29
0
0
18,856
15,306
11,662
29,300
25,550
22,182
17,248
25,201
18,221
9,367
17,574
20,684
13,262
15,301
40,168
34,937
27,937
20,403
19,853
14,967
16,835
22,133
17,034
18,807
14,062
19,910
21,549
18,420
54,605
51,295
49,099
47,795
43,123
39,323
36,754

36,754

39,323

43,123

47,795

49,099

51,295

54,605

18,420

21,549

19,910

14,062

18,807

17,034

22,133

16,835

14,967

19,853

20,403

27,937

34,937

40,168

15,301

13,262

20,684

17,574

9,367

18,221

25,201

17,248

22,182

25,550

29,300

11,662

15,306

18,856

Cash And Cash Equivalents

5
13
30
29
29
0
0
14,576
10,965
7,176
25,190
21,133
16,251
11,238
19,552
12,314
4,661
12,800
16,846
9,426
10,701
33,439
27,813
20,572
13,890
12,995
7,655
9,236
13,262
8,058
10,872
8,516
13,260
14,549
12,862
49,539
45,938
43,439
40,406
36,176
31,912
29,180

29,180

31,912

36,176

40,406

43,439

45,938

49,539

12,862

14,549

13,260

8,516

10,872

8,058

13,262

9,236

7,655

12,995

13,890

20,572

27,813

33,439

10,701

9,426

16,846

12,800

4,661

12,314

19,552

11,238

16,251

21,133

25,190

7,176

10,965

14,576

Net Receivables

0
0
0
0
0
0
0
1,775
1,494
1,922
1,549
1,455
2,394
2,185
2,069
2,383
1,606
2,234
1,780
1,282
2,107
2,168
2,760
3,574
3,547
2,988
3,660
3,793
4,541
5,206
5,208
2,658
3,741
4,450
3,389
2,276
2,756
3,121
4,662
3,346
3,341
3,398

3,398

3,341

3,346

4,662

3,121

2,756

2,276

3,389

4,450

3,741

2,658

5,208

5,206

4,541

3,793

3,660

2,988

3,547

3,574

2,760

2,168

2,107

1,282

1,780

2,234

1,606

2,383

2,069

2,185

2,394

1,455

1,549

1,922

1,494

1,775

Other Current Assets

0
0
0
0
0
0
0
1,381
1,570
1,700
1,939
2,124
2,349
2,646
2,524
993
692
625
502
735
597
2,183
1,339
958
584
509
281
506
606
428
238
405
525
370
191
636
648
788
485
829
796
668

668

796

829

485

788

648

636

191

370

525

405

238

428

606

506

281

509

584

958

1,339

2,183

597

735

502

625

692

993

2,524

2,646

2,349

2,124

1,939

1,700

1,570

1,381

> Long-term Assets

0
0
0
0
0
0
0
2,945
3,292
3,756
4,174
4,483
4,724
4,878
6,997
4,330
4,208
4,047
3,741
3,633
3,631
3,237
3,051
3,022
2,805
2,570
2,688
4,025
3,450
3,258
3,108
2,882
2,439
1,937
2,177
1,899
1,678
1,634
1,371
1,119
1,197
2,557

2,557

1,197

1,119

1,371

1,634

1,678

1,899

2,177

1,937

2,439

2,882

3,108

3,258

3,450

4,025

2,688

2,570

2,805

3,022

3,051

3,237

3,631

3,633

3,741

4,047

4,208

4,330

6,997

4,878

4,724

4,483

4,174

3,756

3,292

2,945

Property Plant Equipment

0
0
0
0
0
0
0
1,764
1,840
1,957
2,102
2,183
2,154
2,399
2,625
2,617
2,579
2,561
2,435
2,458
2,562
2,301
2,249
2,350
2,271
2,170
2,365
3,696
3,093
2,897
2,741
2,511
2,133
1,819
1,857
1,664
1,515
1,509
1,207
978
1,069
2,333

2,333

1,069

978

1,207

1,509

1,515

1,664

1,857

1,819

2,133

2,511

2,741

2,897

3,093

3,696

2,365

2,170

2,271

2,350

2,249

2,301

2,562

2,458

2,435

2,561

2,579

2,617

2,625

2,399

2,154

2,183

2,102

1,957

1,840

1,764

Goodwill

0
0
0
0
0
0
0
0
0
0
0
0
0
0
189
189
189
189
189
189
189
189
189
189
189
189
189
189
189
189
189
189
189
0
0
0
0
0
0
0
0
0

189

Intangible Assets

0
0
0
0
0
0
0
0
0
0
55
0
0
0
1,584
1,431
1,297
1,162
1,026
894
762
626
491
359
225
90
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

225

359

491

626

762

894

1,026

1,162

1,297

1,431

1,584

Other Assets

0
0
0
0
0
0
0
1,181
1,451
1,799
2,072
2,300
2,570
2,479
4,372
1,713
1,629
1,486
1,306
1,175
1,069
936
802
124
120
121
134
140
168
172
178
182
117
118
1,005
235
163
125
164
141
128
224

224

128

141

164

125

163

235

1,005

118

117

182

178

172

168

140

134

121

120

124

802

936

1,069

1,175

1,306

1,486

1,629

1,713

4,372

2,479

2,570

2,300

2,072

1,799

1,451

1,181

Deferred Long Term Asset Charges

0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,502
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

2,502

> Total Liabilities

10
19
19
14
14
10
16
96,337
36,706
21,340
10,674
10,936
12,971
12,880
23,390
15,798
12,014
13,393
17,894
18,278
17,304
13,738
16,597
16,120
15,582
16,836
14,927
16,326
20,179
13,871
15,118
11,716
22,377
15,085
16,163
15,529
12,877
11,671
11,947
10,756
8,791
10,697

10,697

8,791

10,756

11,947

11,671

12,877

15,529

16,163

15,085

22,377

11,716

15,118

13,871

20,179

16,326

14,927

16,836

15,582

16,120

16,597

13,738

17,304

18,278

17,894

13,393

12,014

15,798

23,390

12,880

12,971

10,936

10,674

21,340

36,706

96,337

> Total Current Liabilities

10
19
19
14
14
10
16
5,613
6,105
5,896
6,614
6,708
8,357
8,256
8,619
7,849
5,792
5,506
6,314
7,021
6,587
6,592
9,165
10,028
9,395
10,185
10,132
9,710
9,343
8,087
7,832
7,550
7,129
5,233
4,974
5,981
4,681
4,675
6,855
5,970
4,819
7,858

7,858

4,819

5,970

6,855

4,675

4,681

5,981

4,974

5,233

7,129

7,550

7,832

8,087

9,343

9,710

10,132

10,185

9,395

10,028

9,165

6,592

6,587

7,021

6,314

5,506

5,792

7,849

8,619

8,256

8,357

6,708

6,614

5,896

6,105

5,613

Short-term Debt

0
0
18
9
9
9
11
39
40
41
41
42
43
79
80
81
78
67
54
432
972
1,556
2,173
2,367
2,368
2,368
2,368
2,775
2,762
2,768
2,772
2,604
2,702
406
548
1,361
514
372
229
97
51
244

244

229

372

514

1,361

548

406

2,702

2,604

2,772

2,768

2,762

2,775

2,368

2,367

2,173

1,556

972

432

Short Long Term Debt

0
0
0
0
0
0
0
0
0
0
41
0
0
0
80
0
0
0
6,843
432
972
1,556
2,139
2,333
2,333
2,333
2,333
2,333
2,333
2,333
2,333
2,170
2,433
0
0
814
0
0
0
0
0
1,996

1,996

814

2,433

2,170

2,333

2,139

1,556

972

432

6,843

Accounts payable

0
0
0
0
0
0
4
1,044
1,227
1,077
783
1,464
2,306
2,148
2,694
3,618
2,074
1,359
1,879
2,867
2,068
990
2,420
3,392
2,590
3,438
3,156
2,474
2,480
1,362
1,903
1,999
1,902
1,813
1,501
1,652
1,428
1,308
3,107
2,939
2,045
2,387

2,387

2,045

2,939

3,107

1,308

1,428

1,652

1,501

1,813

1,902

1,999

1,903

1,362

2,480

2,474

3,156

3,438

2,590

3,392

2,420

990

2,068

2,867

1,879

1,359

2,074

3,618

2,694

2,148

2,306

1,464

783

1,077

1,227

1,044

Other Current Liabilities

10
19
1
0
5
1
1
1,570
1,267
1,323
2,378
1,657
1,976
2,190
1,885
2,928
2,930
2,982
3,556
2,747
2,599
2,804
3,469
2,977
3,127
3,434
3,506
3,250
2,732
2,559
1,665
1,716
1,180
1,566
1,429
1,475
1,317
1,704
2,299
1,819
1,583
4,168

4,168

1,583

1,819

2,299

1,704

1,317

1,475

1,429

1,566

1,180

1,716

1,665

2,559

2,732

3,250

3,506

3,434

3,127

2,977

3,469

2,804

2,599

2,747

3,556

2,982

2,930

2,928

1,885

2,190

1,976

1,657

2,378

1,323

1,267

1,570

> Long-term Liabilities

0
0
0
0
0
0
0
90,724
30,601
15,444
4,060
4,228
4,614
4,624
14,771
7,949
6,222
7,887
11,580
11,257
10,717
7,146
7,432
6,092
6,187
6,651
4,795
6,616
10,836
5,784
7,286
4,166
15,248
9,852
11,189
9,548
8,196
6,996
5,092
4,786
3,972
2,839

2,839

3,972

4,786

5,092

6,996

8,196

9,548

11,189

9,852

15,248

4,166

7,286

5,784

10,836

6,616

4,795

6,651

6,187

6,092

7,432

7,146

10,717

11,257

11,580

7,887

6,222

7,949

14,771

4,624

4,614

4,228

4,060

15,444

30,601

90,724

Long term Debt Total

0
0
0
0
0
0
0
88,162
0
11,908
77
0
0
225
9,195
6,210
4,545
6,165
10,335
0
0
0
0
0
4,874
3,199
2,648
2,105
1,538
972
407
1,788
13,005
7,639
9,112
7,763
6,617
0
0
0
0
0

6,617

7,763

9,112

7,639

13,005

1,788

407

972

1,538

2,105

2,648

3,199

4,874

10,335

6,165

4,545

6,210

9,195

225

11,908

88,162

Deferred Long Term Asset Charges

0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,502
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

2,502

Other Liabilities

0
0
0
0
0
0
0
90,613
30,502
15,356
3,983
4,163
4,561
4,624
14,625
7,824
6,114
7,788
4,701
4,730
4,738
1,713
2,546
1,755
2,406
3,425
2,147
3,505
8,364
3,994
6,168
3,571
14,096
6,400
7,881
7,187
6,205
5,004
3,099
2,792
1,863
1,672

1,672

1,863

2,792

3,099

5,004

6,205

7,187

7,881

6,400

14,096

3,571

6,168

3,994

8,364

3,505

2,147

3,425

2,406

1,755

2,546

1,713

4,738

4,730

4,701

7,788

6,114

7,824

14,625

4,624

4,561

4,163

3,983

15,356

30,502

90,613

Deferred Long Term Liability

0
0
0
0
0
0
0
2,562
0
3,536
3,983
0
0
4,399
4,613
766
747
822
805
776
653
685
816
766
1,201
1,535
0
36
36
36
36
66
0
0
0
0
0
0
0
0
0
0

1,535

1,201

766

816

685

653

776

805

822

747

766

4,613

4,399

3,983

3,536

2,562

> Total Stockholder Equity

-5
-6
11
0
15
-10
-16
-74,536
-18,109
-5,922
22,800
19,097
13,935
9,246
8,808
6,753
1,561
8,228
6,531
-1,383
1,628
29,667
21,391
14,839
7,626
5,587
2,728
4,534
5,404
6,421
6,797
5,228
-28
8,401
4,434
40,975
40,096
39,062
37,219
33,486
31,729
28,614

28,614

31,729

33,486

37,219

39,062

40,096

40,975

4,434

8,401

-28

5,228

6,797

6,421

5,404

4,534

2,728

5,587

7,626

14,839

21,391

29,667

1,628

-1,383

6,531

8,228

1,561

6,753

8,808

9,246

13,935

19,097

22,800

-5,922

-18,109

-74,536

-16

-10

-6

-5

Common Stock

5
5
6
0
6
6
6
78
79
79
102
102
102
102
105
109
16
21
22
22
26
60
60
60
61
63
63
68
75
75
87
6
8
8
8
13
13
13
13
13
13
13

109

105

102

Retained Earnings

-220,769

-216,465

-213,487

-208,867

-206,004

-204,046

-202,773

-199,103

-195,127

-197,579

-185,812

-183,278

-180,557

-180,763

-177,697

-171,146

-167,014

-160,031

-152,055

-144,154

-135,176

-128,841

-123,334

-114,861

-109,284

-100,806

-95,042

-91,391

-86,746

-81,561

-75,916

-71,801

-51,646

-63,670

-119,797

-48

-42

-17

-13

-11

-10

Capital Surplus

0
0
0
0
0
0
26
45,183
0
45,645
94,499
0
0
95,890
100,094
101,686
102,341
117,498
121,291
121,880
130,598
165,060
165,825
167,381
167,823
172,721
173,903
182,107
186,142
186,629
189,938
190,811
197,513
203,905
204,376
244,117
244,636
0
0
0
0
0

244,636

244,117

204,376

203,905

197,513

190,811

189,938

186,629

186,142

182,107

173,903

172,721

167,823

167,381

165,825

165,060

130,598

121,880

121,291

117,498

102,341

101,686

100,094

95,890

94,499

45,645

45,183

Treasury Stock

Other Stockholders Equity

0
0
18
0
26
26
26
45,183
45,483
45,645
96,001
94,911
95,394
95,890
102,347
101,686
102,341
117,498
121,291
121,880
130,598
165,060
165,825
167,381
167,823
172,721
173,903
182,107
186,142
186,629
189,938
190,811
197,513
203,905
204,376
244,117
244,636
245,299
246,090
246,765
247,347
247,884

247,884

247,347

246,765

246,090

245,299

244,636

244,117

204,376

203,905

197,513

190,811

189,938

186,629

186,142

182,107

173,903

172,721

167,823

167,381

165,825

165,060

130,598

121,880

121,291

117,498

102,341

101,686

102,347

95,890

95,394

94,911

96,001

45,645

45,483

45,183

Balance Sheet

Currency in USD. All numbers in thousands.

	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31
Accounts Payable	3,107	1,501	1,903	3,156	2,420	1,879	2,694	783	-	-	-
Accumulated Other Comprehensive Income	-17	-847	50	-92	-340	79	-2,253	-1,502	-	-	-
Capital Lease Obligations	229	781	1,150	35	34	54	-	-	-	-	-
Capital Stock	13	8	87	63	-	-	-	-	-	-	-
Capital Surpluse	-	204,376	189,938	173,903	165,825	121,291	100,094	94,499	-	-	-
Cash	40,406	12,862	10,872	7,655	27,813	16,846	19,552	25,190	29	29	8
Cash And Short Term Investments	40,406	12,862	10,872	7,655	27,813	16,846	19,552	25,190	29	-	8
Common Stock	13	8	87	63	60	22	105	102	6	-	5
Common Stock Shares Outstanding	12,269	7,164	4,794	4,082	2,374	1,241	1,262	966	271	3,733	-
Common Stock Total Equity	-	8	87	63	60	22	105	102	6	6	5
Current Deferred Revenue	1,220	1,496	1,492	1,102	1,103	825	3,960	3,412	-	-	-
Deferred Long Term Asset Charges	-	-	-	-	-	-	2,502	-	-	-	-
Deferred Long Term Liab	-	-	36	-	816	805	2,502	3,983	-	-	-
Good Will	-	0	189	189	189	189	189	-	-	-	-
Intangible Assets	-	-	-	-	491	1,026	1,584	55	-	-	-
Inventory	2,242	1,978	2,489	3,371	3,025	1,556	1,056	622	-	-	-
Liabilities And Stockholders Equity	49,166	20,597	21,915	17,655	37,988	24,425	32,198	33,474	29	29	8
Long Term Debt	1,993	9,112	407	2,648	4,830	6,789	146	77	-	-	-
Long Term Debt Total	-	9,112	407	2,648	4,830	6,789	9,195	77	-	-	-
Net Debt	-38,184	-9,006	-7,693	-2,639	-20,810	-10,003	-19,472	-25,072	-20	-20	-5
Net Invested Capital	39,212	7,509	9,537	7,709	28,360	-	-	-	-	-	-
Net Receivables	4,662	3,389	5,208	3,660	2,760	1,780	2,069	1,549	-	-	-
Net Tangible Assets	37,219	4,434	6,608	2,539	20,711	5,316	7,035	22,800	-	-	-
Net Working Capital	40,940	13,446	10,975	4,835	25,772	-	-	-	-	-	-
Non Current Assets Total	1,371	2,177	3,108	2,688	3,051	3,741	6,997	4,174	-	-	-
Non Current Liabilities Other	74	2,077	72	67	138	440	963	-	-	-	-
Non Current Liabilities Total	5,092	11,189	7,286	4,795	7,432	11,580	14,771	4,060	-	-	-
Non Currrent Assets Other	164	320	178	134	122	91	2,599	2,072	-	-	-
Other Assets	164	1,005	178	134	122	91	2,599	2,072	-	-	-
Other Current Assets	485	191	238	281	1,339	502	2,524	1,939	-	-	-
Other Current Liab	2,299	1,429	1,665	3,506	3,469	3,556	1,885	2,378	5	-	5
Other Liab	3,099	7,881	6,168	2,199	2,602	4,776	14,771	3,983	-	-	-
Other Stockholder Equity	246,090	204,376	189,938	173,903	165,825	121,291	102,347	96,001	26	-	-
Property Plant And Equipment Gross	-	1,857	2,741	2,365	2,249	2,435	2,625	2,102	-	-	-
Property Plant And Equipment Net	1,207	1,857	2,741	2,365	2,249	2,435	2,625	2,102	-	-	-
Property Plant Equipment	1,207	1,172	2,741	2,365	2,249	2,435	2,625	2,102	-	-	-
Retained Earnings	-208,867	-199,103	-183,278	-171,146	-144,154	-114,861	-91,391	-71,801	-17	-17	-5
Retained Earnings Total Equity	-	-199,103	-	-	-144,154	-114,861	-91,391	-71,801	-	-	-
Short Long Term Debt	-	-	2,333	2,333	2,139	6,843	80	41	-	-	-
Short Long Term Debt Total	2,222	3,856	3,179	5,016	7,003	6,843	80	118	9	9	4
Short Term Debt	229	548	2,772	2,368	2,173	54	80	41	9	9	4
Total Assets	49,166	20,597	21,915	17,655	37,988	24,425	32,198	33,474	29	29	8
Total Current Assets	47,795	18,420	18,807	14,967	34,937	20,684	25,201	29,300	29	29	8
Total Current Liabilities	6,855	4,974	7,832	10,132	9,165	6,314	8,619	6,614	14	14	8
Total Liab	11,947	16,163	15,118	14,927	16,597	17,894	23,390	10,674	14	14	8
Total Stockholder Equity	37,219	4,434	6,797	2,728	21,391	6,531	8,808	22,800	15	-	0

	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30
Accounts Payable	2,387	2,045	2,939	3,107	1,308	1,428	1,652	1,501	1,813	1,902	1,999	1,903	1,362	2,480	2,474	3,156	3,438	2,590	3,392	2,420	990	2,068	2,867	1,879	1,359	2,074	3,618	2,694	2,148	2,306	1,464	783	1,077	1,227	1,044	4	-	-	-	-	-	-
Accumulated Other Comprehensive Income	1,486	834	195	-17	-246	-507	-382	-847	-385	30	223	50	274	-50	56	-92	-183	-227	-547	-340	-277	-155	49	79	-7	10	-2,253	-2,253	-	-	-1,502	-1,502	-	-	-	-	-	-	-	-	-	-
Capital Lease Obligations	1,411	165	97	229	372	514	646	781	779	777	1,029	1,150	1,253	1,363	1,448	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Capital Stock	13	13	13	13	13	13	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Capital Surpluse	-	-	-	-	-	244,636	244,117	204,376	203,905	197,513	190,811	189,938	186,629	186,142	182,107	173,903	172,721	167,823	167,381	165,825	165,060	130,598	121,880	121,291	117,498	102,341	101,686	100,094	95,890	-	-	94,499	45,645	-	45,183	26	-	-	-	-	-	-
Cash	29,180	31,912	36,176	40,406	43,439	45,938	49,539	12,862	14,549	13,260	8,516	10,872	8,058	13,262	9,236	7,655	12,995	13,890	20,572	27,813	33,439	10,701	9,426	16,846	12,800	4,661	12,314	19,552	11,238	16,251	21,133	25,190	7,176	10,965	14,576	0	0	29	29	30	13	5
Cash And Short Term Investments	29,180	31,912	36,176	40,406	43,439	45,938	49,539	12,862	14,549	13,260	8,516	10,872	8,058	13,262	9,236	7,655	12,995	13,890	20,572	27,813	33,439	10,701	9,426	16,846	12,800	4,661	12,314	19,552	11,238	16,251	21,133	25,190	7,176	10,965	14,576	0	0	29	-	30	13	5
Common Stock	13	13	13	13	13	13	13	8	8	8	6	87	75	75	68	63	63	61	60	60	60	26	22	22	21	16	109	105	102	102	102	102	79	79	78	6	6	6	-	6	5	5
Common Stock Shares Outstanding	13,071	12,884	12,678	12,678	12,710	12,737	10,752	10,752	8,379	6,261	5,803	5,120	4,997	4,713	4,338	4,182	4,092	4,041	4,010	4,010	2,315	2,204	1,461	1,321	1,642	1,404	1,329	1,269	1,262	1,260	1,256	1,087	1,028	1,170	828	271	271	214	214	214	214	214
Common Stock Total Equity	-	-	-	-	-	13	13	8	8	8	6	87	75	75	68	63	63	61	60	60	60	26	22	22	21	16	109	105	102	102	102	102	79	79	78	6	6	6	6	6	5	5
Current Deferred Revenue	1,059	1,140	1,115	1,220	1,291	1,422	1,493	1,496	1,448	1,345	1,231	1,492	1,398	1,369	1,211	1,102	945	1,310	1,292	1,103	1,242	948	975	825	1,098	710	1,222	3,960	3,839	4,032	3,545	3,412	3,455	3,571	2,960	-	-	-	-	-	-	-
Deferred Long Term Asset Charges	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2,502	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Long Term Liab	-	-	-	-	-	-	-	-	-	-	66	36	36	36	36	-	1,535	1,201	766	816	685	653	776	805	822	747	766	4,613	4,399	-	-	3,983	3,536	-	2,562	-	-	-	-	-	-	-
Good Will	-	-	-	-	-	-	-	0	0	189	189	189	189	189	189	189	189	189	189	189	189	189	189	189	189	189	189	189	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Intangible Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	90	225	359	491	626	762	894	1,026	1,162	1,297	1,431	1,584	-	-	-	55	-	-	-	-	-	-	-	-	-	-
Inventory	3,508	3,274	2,772	2,242	1,751	1,953	2,154	1,978	2,180	2,384	2,483	2,489	3,342	3,724	3,300	3,371	3,361	2,382	2,833	3,025	2,378	1,896	1,819	1,556	1,915	2,408	2,531	1,056	1,179	1,188	838	622	864	1,277	1,123	-	-	-	-	-	-	-
Liabilities And Stockholders Equity	39,311	40,520	44,242	49,166	50,733	52,973	56,504	20,597	23,486	22,349	16,944	21,915	20,292	25,583	20,860	17,655	22,423	23,208	30,959	37,988	43,405	18,932	16,895	24,425	21,621	13,575	22,551	32,198	22,126	26,906	30,033	33,474	15,418	18,598	21,801	0	0	29	29	30	13	5
Long Term Debt	-	1,995	1,994	1,993	1,992	1,991	2,262	9,112	7,639	644	1,788	407	972	1,535	2,093	2,648	3,199	4,874	4,290	4,886	5,433	5,979	6,527	10,335	6,165	4,545	6,210	9,195	225	53	65	77	11,908	100	88,162	-	-	-	-	-	-	-
Long Term Debt Total	-	-	-	-	-	6,617	7,763	9,112	7,639	13,005	1,788	407	972	1,538	2,105	2,648	3,199	4,874	-	-	-	-	-	10,335	6,165	4,545	6,210	9,195	225	-	-	77	11,908	-	88,162	-	-	-	-	-	-	-
Net Debt	-27,769	-29,752	-34,085	-38,184	-41,075	-43,433	-45,817	-9,006	-10,691	-9,406	-5,317	-7,693	-4,318	-8,965	-4,368	-2,639	-7,428	-7,776	-13,915	-20,810	-26,515	-3,823	-2,549	-10,003	-12,733	-4,583	-12,233	-19,472	-11,159	-16,155	-21,026	-25,072	-7,047	-10,825	-14,426	11	9	-20	-20	-12	-13	-5
Net Invested Capital	30,610	33,724	35,480	39,212	41,054	42,087	44,051	7,509	11,480	3,049	7,398	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Receivables	3,398	3,341	3,346	4,662	3,121	2,756	2,276	3,389	4,450	3,741	2,658	5,208	5,206	4,541	3,793	3,660	2,988	3,547	3,574	2,760	2,168	2,107	1,282	1,780	2,234	1,606	2,383	2,069	2,185	2,394	1,455	1,549	1,922	1,494	1,775	-	-	-	-	-	-	-
Net Tangible Assets	28,614	31,729	33,486	37,219	39,062	40,096	40,975	4,434	8,401	-217	5,039	6,608	6,232	5,215	4,345	2,539	5,308	7,212	14,291	20,711	28,852	677	-2,466	5,316	8,228	1,561	5,133	7,035	9,246	-	-	22,800	-5,922	-	-74,536	-16	-	-	-	-	-	-
Net Working Capital	28,896	34,504	37,153	40,940	44,424	46,614	48,624	13,446	16,316	12,781	6,512	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non Current Assets Total	2,557	1,197	1,119	1,371	1,634	1,678	1,899	2,177	1,937	2,439	2,882	3,108	3,258	3,450	4,025	2,688	2,570	2,805	3,022	3,051	3,237	3,631	3,633	3,741	4,047	4,208	4,330	6,997	4,878	4,724	4,483	4,174	3,756	3,292	2,945	-	-	-	-	-	-	-
Non Current Liabilities Other	101	69	60	74	54	53	42	2,077	2,213	29	45	72	17	45	54	-	80	112	-	-	-	-	-	440	900	930	973	963	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non Current Liabilities Total	2,839	3,972	4,786	5,092	6,996	8,196	9,548	11,189	9,852	15,248	4,166	7,286	5,784	10,836	6,616	4,795	6,651	6,187	6,092	7,432	7,146	10,717	11,257	11,580	7,887	6,222	7,949	14,771	4,624	4,614	4,228	4,060	15,444	30,601	90,724	-	-	-	-	-	-	-
Non Currrent Assets Other	224	128	141	164	125	163	235	320	118	117	182	178	172	168	140	134	121	120	124	122	121	118	92	91	135	143	93	2,599	2,479	2,570	2,300	2,072	1,799	1,452	1,182	-	-	-	-	-	-	-
Other Assets	224	128	141	164	125	163	235	1,005	118	117	182	178	172	168	140	134	121	120	124	802	936	1,069	1,175	1,306	1,486	1,629	1,713	4,372	2,479	2,570	2,300	2,072	1,799	1,451	1,181	-	-	-	-	-	-	-
Other Current Assets	668	796	829	485	788	648	636	191	370	525	405	238	428	606	506	281	509	584	958	1,339	2,183	597	735	502	625	692	993	2,524	2,646	2,349	2,124	1,939	1,700	1,570	1,381	-	-	-	-	-	-	-
Other Current Liab	4,168	1,583	1,819	2,299	1,704	1,317	1,475	1,429	1,566	1,180	1,716	1,665	2,559	2,732	3,250	3,506	3,434	3,127	2,977	3,469	2,804	2,599	2,747	3,556	2,982	2,930	2,928	1,885	2,190	1,976	1,657	2,378	1,323	1,267	1,570	1	1	5	-	1	19	10
Other Liab	1,672	1,863	2,792	3,099	5,004	6,205	7,187	7,881	6,400	14,096	3,571	6,168	3,994	8,364	3,505	2,147	3,425	2,406	1,755	2,546	1,713	4,738	4,730	4,701	7,788	6,114	7,824	14,625	4,624	4,561	4,163	3,983	15,356	30,502	90,613	-	-	-	-	-	-	-
Other Stockholder Equity	247,884	247,347	246,765	246,090	245,299	244,636	244,117	204,376	203,905	197,513	190,811	189,938	186,629	186,142	182,107	173,903	172,721	167,823	167,381	165,825	165,060	130,598	121,880	121,291	117,498	102,341	101,686	102,347	95,890	95,394	94,911	96,001	45,645	45,483	45,183	26	26	26	-	18	-	-
Property Plant And Equipment Gross	-	-	-	-	-	1,515	1,664	1,857	1,819	2,133	2,511	2,741	2,897	3,093	3,696	2,365	2,170	2,271	2,350	2,249	2,301	2,562	2,458	2,435	2,561	2,579	2,617	2,625	2,399	2,154	2,183	2,102	1,957	1,840	1,764	-	-	-	-	-	-	-
Property Plant And Equipment Net	2,333	1,069	978	1,207	1,509	1,515	1,664	1,857	1,819	2,133	2,511	2,741	2,897	3,093	3,696	2,365	2,170	2,271	2,350	2,249	2,301	2,562	2,458	2,435	2,561	2,579	2,617	2,625	2,399	2,154	2,183	2,102	1,957	1,840	1,764	-	-	-	-	-	-	-
Property Plant Equipment	2,333	1,069	978	1,207	1,509	1,515	1,664	1,172	1,033	2,133	2,511	2,741	2,897	3,093	3,696	2,365	2,170	2,271	2,350	2,249	2,301	2,562	2,458	2,435	2,561	2,579	2,617	2,625	2,399	2,154	2,183	2,102	1,957	1,841	1,764	-	-	-	-	-	-	-
Retained Earnings	-220,769	-216,465	-213,487	-208,867	-206,004	-204,046	-202,773	-199,103	-195,127	-197,579	-185,812	-183,278	-180,557	-180,763	-177,697	-171,146	-167,014	-160,031	-152,055	-144,154	-135,176	-128,841	-123,334	-114,861	-109,284	-100,806	-95,042	-91,391	-86,746	-81,561	-75,916	-71,801	-51,646	-63,670	-119,797	-48	-42	-17	-17	-13	-11	-10
Retained Earnings Total Equity	-	-	-	-	-	-204,046	-202,773	-199,103	-195,127	-197,579	-185,812	-	-	-	-177,697	-	-167,014	-160,031	-152,055	-144,154	-135,176	-128,841	-123,334	-114,861	-109,284	-100,806	-95,042	-91,391	-86,746	-	-	-71,801	-51,646	-	-119,797	-48	-	-	-	-	-	-
Short Long Term Debt	1,996	-	-	-	-	-	814	-	-	2,433	2,170	2,333	2,333	2,333	2,333	2,333	2,333	2,333	2,333	2,139	1,556	972	432	6,843	-	-	-	80	-	-	-	41	-	-	-	-	-	-	-	-	-	-
Short Long Term Debt Total	1,411	2,160	2,091	2,222	2,364	2,505	3,722	3,856	3,858	3,854	3,199	3,179	3,740	4,297	4,868	5,016	5,567	6,114	6,657	7,003	6,924	6,878	6,877	6,843	67	78	81	80	79	96	107	118	129	140	151	11	9	9	9	18	-	-
Short Term Debt	244	51	97	229	372	514	1,361	548	406	2,702	2,604	2,772	2,768	2,762	2,775	2,368	2,368	2,368	2,367	2,173	1,556	972	432	54	67	78	81	80	79	43	42	41	41	40	39	11	9	9	9	18	-	-
Total Assets	39,311	40,520	44,242	49,166	50,733	52,973	56,504	20,597	23,486	22,349	16,944	21,915	20,292	25,583	20,860	17,655	22,423	23,208	30,959	37,988	43,405	18,932	16,895	24,425	21,621	13,575	22,551	32,198	22,126	26,906	30,033	33,474	15,418	18,598	21,801	0	0	29	29	30	13	5
Total Current Assets	36,754	39,323	43,123	47,795	49,099	51,295	54,605	18,420	21,549	19,910	14,062	18,807	17,034	22,133	16,835	14,967	19,853	20,403	27,937	34,937	40,168	15,301	13,262	20,684	17,574	9,367	18,221	25,201	17,248	22,182	25,550	29,300	11,662	15,306	18,856	0	0	29	29	30	13	5
Total Current Liabilities	7,858	4,819	5,970	6,855	4,675	4,681	5,981	4,974	5,233	7,129	7,550	7,832	8,087	9,343	9,710	10,132	10,185	9,395	10,028	9,165	6,592	6,587	7,021	6,314	5,506	5,792	7,849	8,619	8,256	8,357	6,708	6,614	5,896	6,105	5,613	16	10	14	14	19	19	10
Total Liab	10,697	8,791	10,756	11,947	11,671	12,877	15,529	16,163	15,085	22,377	11,716	15,118	13,871	20,179	16,326	14,927	16,836	15,582	16,120	16,597	13,738	17,304	18,278	17,894	13,393	12,014	15,798	23,390	12,880	12,971	10,936	10,674	21,340	36,706	96,337	16	10	14	14	19	19	10
Total Stockholder Equity	28,614	31,729	33,486	37,219	39,062	40,096	40,975	4,434	8,401	-28	5,228	6,797	6,421	5,404	4,534	2,728	5,587	7,626	14,839	21,391	29,667	1,628	-1,383	6,531	8,228	1,561	6,753	8,808	9,246	13,935	19,097	22,800	-5,922	-18,109	-74,536	-16	-10	15	-	11	-6	-5

Cash Flow

Currency in USD. All numbers in thousands.

	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31
Begin Period Cash Flow	12,862	10,872	7,655	27,813	16,846	19,552	25,190	805	8	8
Capital Expenditures	59	59	60	131	456	1,096	1,492	1,487	0	0
Cash And Cash Equivalents Changes	-	1,949	-	-20,158	10,967	-2,706	-5,638	24,385	-	-
Cash Flows Other Operating	-	3,455	-	160	-3,408	48	-3,131	-2,031	-	-
Change In Cash	27,544	1,990	3,217	-20,158	10,967	-2,706	-5,638	24,385	21	21
Change In Working Capital	-468	1,123	-2,019	530	-3,577	-2,150	678	230	0	0
Change Receivables	-	1,754	-	-850	-1,085	154	-520	-1,000	-	-
Change To Account Receivables	-1,624	1,754	-1,599	-850	-1,085	154	-520	-1,000	-	-
Change To Inventory	-752	379	893	-1,655	-2,096	-541	-200	354	-	-
Change To Liabilities	1,048	-1,278	-547	1,989	361	-7,761	3,004	2,907	-	-
Change To Netincome	-1,485	2,112	-3,537	3,516	-454	-1,218	-720	17,595	-	-
Change To Operating Activities	860	-629	-766	1,605	-757	5,998	-1,606	-1,087	-	-
Depreciation	561	620	690	1,515	1,732	1,855	933	745	-	-
End Period Cash Flow	40,406	12,862	10,872	7,655	27,813	16,846	19,552	25,190	29	29
Exchange Rate Changes	-	-	-	-135	81	80	-	-	-	-
Free Cash Flow	-11,215	-8,755	-15,832	-22,296	-31,682	-26,093	-19,761	-16,494	-12	-12
Investments	-59	0	-60	-131	-456	-1,096	-	-	-	-
Issuance Of Capital Stock	37,295	7,082	21,188	4,446	-	-	-	-	-	-
Net Borrowings	-	288	-2,377	-2,174	-54	6,851	-60	-2,596	-	-
Net Income	-9,764	-15,825	-12,132	-26,992	-29,122	-23,470	-19,590	-33,769	-12	-12
Other Cashflows From Financing Activities	1,417	6,412	228	1	159	8,865	14,183	21,514	6	-
Other Non Cash Items	-3,985	2,748	-4,566	-86	-2,673	-4,353	-2,021	16,644	35	-
Sale Purchase Of Stock	-	10,416	21,416	4,447	42,622	-173	14,183	43,475	-	-
Total Cash From Financing Activities	38,712	10,704	19,039	2,273	42,568	23,307	14,123	40,879	33	33
Total Cash From Operating Activities	-11,156	-8,755	-15,772	-22,165	-31,226	-24,997	-18,269	-15,007	-12	-12
Total Cashflows From Investing Activities	-59	-59	-60	-131	-456	-1,096	-1,492	-1,487	-	-

	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30
Begin Period Cash Flow	31,912	36,176	40,406	43,439	45,938	49,539	12,862	14,549	13,260	8,516	10,872	8,058	13,262	9,236	7,655	12,995	13,890	20,572	27,813	33,439	10,701	9,426	16,846	12,800	4,661	12,314	19,552	11,238	16,251	21,133	25,190	7,176	10,965	14,576	805	0	2	30	30	13	5	8
Capital Expenditures	141	175	141	59	60	162	60	162	0	0	0	60	60	53	7	80	20	20	31	103	105	110	138	368	131	312	285	530	403	278	281	570	243	426	248	0	0	0	0	0	0	0
Cash And Cash Equivalents Changes	-	-	-	-	-	3,606	40,712	-1,740	1,274	1,282	1,133	-	-5,204	4,026	1,581	-5,340	-895	-6,682	-7,241	-	22,738	1,275	-7,420	-	8,139	-7,653	-7,238	-	-	-	-	-	-	-	13,771	-	-	-	-	-	-	-
Cash Flows Other Operating	-	-	-	-	-	648	37	1,590	-4,167	3,522	2,510	-	-4,163	-2,729	1,293	-976	798	654	-316	-	-529	-15	-165	-	1,686	-1,364	1,052	-	-	-	-	-	-	-	-686	-	-	-	-	-	-	-
Change In Cash	-2,732	-4,264	-4,230	-3,033	-2,499	-3,601	36,677	-1,687	1,289	4,744	-2,356	2,814	-5,204	4,026	1,581	-5,340	-895	-6,682	-7,241	-5,626	22,738	1,275	-7,420	4,046	8,139	-7,653	-7,238	8,314	-5,013	-4,882	-4,057	18,014	-3,789	-3,611	13,771	0	-1	-1	-1	17	7	-3
Change In Working Capital	-1,392	-1,943	-625	403	-516	-967	612	393	224	-1,742	2,248	609	-1,236	-194	-1,198	-1,030	670	363	527	884	-2,664	-1,892	95	1,387	-479	-900	-2,158	699	-128	404	-297	1,648	-141	669	-1,946	4	-1	4	4	17	-1	-4
Change Receivables	-	-	-	-	-	497	-917	1,039	-705	3,970	-2,550	-	-677	-743	-188	-741	569	120	-798	-	-106	-880	498	-	-619	727	-314	-	-	-	-	-	-	-	-1,226	-	-	-	-	-	-	-
Change To Account Receivables	1,044	-69	1,297	-1,614	-430	-497	917	1,039	-705	-1,130	2,550	9	-677	-743	-188	-741	569	120	-798	-597	-106	-880	498	285	-634	817	-314	116	209	-939	94	372	-428	281	-1,226	-	-	-	-	-	-	-
Change To Inventory	-1,477	-659	-562	-581	-35	92	-228	11	221	202	-55	698	455	-106	-154	-401	-1,056	88	-286	-857	-403	-366	-470	485	304	145	-1,475	179	99	-217	-261	515	413	-79	-495	-	-	-	-	-	-	-
Change To Liabilities	180	-767	-654	1,765	-290	-413	-14	-756	455	-1,156	179	578	-1,291	695	-714	-103	1,083	-223	1,232	182	-573	-758	301	650	-230	-2,073	-4,406	1,245	1,177	1,121	-	228	-	-	460	-	-	-	-	-	-	-
Change To Netincome	1,197	342	908	-745	-157	-1,514	931	196	325	2,420	-829	39	855	1,145	862	825	1,061	777	853	-454	-1,271	-2,544	394	-1,218	440	538	1,574	-720	-	-	-	17,579	-	-	77,803	-	-	-	-	-	-	-
Change To Operating Activities	607	-448	-706	833	239	-149	-63	-389	590	-799	-31	-676	-10	229	-309	297	336	513	459	-757	-1,403	112	-234	5,998	-	-	-	-1,606	-	-	-	-1,087	-	-	-	-	-	-	-	-	-	-
Depreciation	632	331	131	130	158	147	126	155	145	156	164	171	26	246	247	341	286	460	428	428	423	406	475	474	473	468	440	280	234	219	200	210	202	176	157	-	-	-	-	-	-	-
End Period Cash Flow	29,180	31,912	36,176	40,406	43,439	45,938	49,539	12,862	14,549	13,260	8,516	10,872	8,058	13,262	9,236	7,655	12,995	13,890	20,572	27,813	33,439	10,701	9,426	16,846	12,800	4,661	12,314	19,552	11,238	16,251	21,133	25,190	7,176	10,965	14,576	0	0	29	29	30	13	5
Exchange Rate Changes	-	-	-	-	-	-	-	-	-	-	-	-	-37	11	-4	-2	-39	-28	-66	-	30	69	-30	-	-6	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow	-11,185	-4,248	-4,206	-3,074	-2,535	-3,606	-2,000	-1,740	-1,270	-4,023	-1,722	-1,495	-4,569	-4,584	-5,184	-5,234	-4,227	-6,059	-6,776	-5,747	-8,828	-9,715	-7,392	-4,810	-6,564	-7,645	-7,074	-5,717	-5,023	-4,912	-4,109	-3,281	-3,829	-3,573	-5,811	-2	-1	0	0	-2	-1	-9
Investments	-	-	-	1	-	-	-	0	0	0	0	0	0	-53	-7	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Issuance Of Capital Stock	0	0	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Borrowings	-	-	-	-	-	-	-	-	-5	882	-589	-594	-598	-594	-591	-589	-591	-595	-399	-54	-8	-16	-22	6,851	-2	-37	-19	-60	-	-	-	-2,596	-	-	-2,532	-	-	-	-	-	-	-
Net Income	-11,902	-2,978	-4,620	-2,863	-1,958	-1,273	-3,670	-3,976	2,452	-11,767	-2,534	-2,721	206	-3,066	-6,551	-4,132	-6,983	-7,978	-7,901	-8,978	-6,335	-5,507	-8,302	-5,576	-8,478	-5,765	-3,651	-4,645	-5,185	-5,645	-4,115	-20,155	12,024	56,127	-81,765	-6	-1	-4	-4	-2	-1	-5
Other Cashflows From Financing Activities	-141	175	-	1	-60	-2	1,417	-62,456	4,541	1,871	-	-	-	173	55	-80	1	-	-31	117	-105	10,937	24	8,791	14,711	29	28	14,051	28	41	63	21,514	-243	-426	-145	2	-	-8	-	-	9	5
Other Cashflows From Investing Activities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	103	104	104	-	-	-	-	-	-	-
Other Non Cash Items	-	-279	345	-1,566	-856	-2,087	524	876	-4,664	8,800	-2,187	-129	-4,052	-2,074	1,689	-969	882	694	-691	1,363	-797	-3,323	84	-1,296	1,600	-1,663	-2,994	-1,993	-9	-54	35	15,253	-15,789	-60,445	77,625	-	1	-	-	-17	1	-
Sale Purchase Of Stock	-	-	-	-	-	-	38,712	-	2,549	7,867	-	21,416	16,553	9,193	7,360	4,446	1	-	-	42,622	31,544	18	24	16,456	14,711	29	-173	14,184	-	-	-	46,814	-	-	22,011	-	-	-	-	-	-	-
Total Cash From Financing Activities	0	0	0	0	0	38,712	38,712	-66,720	2,544	8,749	-589	4,269	-598	8,599	6,769	-104	3,371	-595	-399	109	31,536	10,921	2	8,770	14,709	-8	-164	14,031	10	30	52	21,399	40	-39	19,479	2	-	0	0	19	9	5
Total Cash From Operating Activities	-11,044	-4,248	-4,206	-3,075	-2,475	-3,606	-2,000	-1,740	-1,270	-4,023	-1,722	-1,495	-4,569	-4,531	-5,177	-5,154	-4,207	-6,059	-6,745	-5,644	-8,723	-9,605	-7,254	-4,442	-6,433	-7,333	-6,789	-5,187	-4,620	-4,634	-3,828	-2,712	-3,586	-3,146	-5,563	-2	-1	0	0	-2	-1	-9
Total Cashflows From Investing Activities	-141	-141	-141	1	-60	-60	-60	-60	-	-	-	-60	-60	-53	-7	-80	-20	-20	-31	-456	-105	-110	-138	-1,096	-131	-312	-285	-1,492	-	-	-	-1,487	-	-	-145	-	-	-	-	-	-	-

Income Statement

Currency in USD. All numbers in thousands.

	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31
Cost Of Revenue	4,497	3,812	7,153	7,023	5,284	11,274	7,482	3,768	-	-
Depreciation And Amortization	561	620	690	1,515	1,732	1,855	933	745	-	-
Ebit	-9,651	-15,686	-11,748	-26,392	-28,474	-23,454	-19,577	-33,334	-30	-12
Ebitda	-9,090	-15,066	-11,058	-24,877	-26,742	-21,599	-18,644	-32,589	-11	-11
Gross Profit	6,749	5,070	6,764	4,309	2,069	2,947	1,179	1,559	-	-
Income Before Tax	-9,764	-15,825	-12,132	-26,992	-29,122	-23,470	-19,590	-33,769	-12	-12
Income Tax Expense	-	-	-	0	0	0	0	132	-	-
Interest Expense	113	139	384	600	648	16	13	435	0	0
Interest Income	-	-	5,992	463	0	12	2,503	-	-	-
Net Income	-9,764	-15,825	-12,132	-26,992	-29,122	-23,470	-19,590	-33,769	-12	-12
Net Income Applicable To Common Shares	-9,764	-15,825	-12,132	-26,992	-29,122	-33,815	-24,245	-33,769	-	-
Net Income From Continuing Ops	-9,764	-15,825	-12,132	-26,992	-29,122	-23,470	-19,590	-33,769	-	-
Net Interest Income	-113	-468	-1,480	-600	-648	-4	-	-	-	-
Non Operating Income Net Other	-	-2,395	-	-	3,138	4,116	1,971	-	-	-
Non Recurring	-	433	-	-	659	659	659	-	-	-
Operating Income	-13,828	-13,291	-16,639	-27,030	-31,612	-27,586	-21,561	-16,794	-12	-11
Other Operating Expenses	25,074	21,740	30,556	38,397	38,638	42,003	30,222	22,121	11	11
Reconciled Depreciation	561	620	690	1,515	1,732	-	-	-	-	-
Research Development	2,748	2,474	4,596	5,847	9,483	8,879	6,480	3,868	-	-
Selling And Marketing Expenses	7,305	7,752	11,398	13,827	13,156	10,997	9,258	7,085	-	-
Selling General Administrative	10,524	7,702	7,409	11,700	10,715	10,853	7,002	7,400	11	11
Total Operating Expenses	20,577	17,928	23,403	31,374	33,354	30,729	22,740	18,353	11	11
Total Other Income Expense Net	4,064	-2,534	4,507	38	2,490	4,116	1,971	-16,975	1	-1
Total Revenue	11,246	8,882	13,917	11,332	7,353	14,221	8,661	5,327	-	-

	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30
Cost Of Revenue	1,643	1,824	1,358	1,661	1,242	919	675	893	1,084	1,005	831	1,865	1,569	1,702	2,017	1,806	1,467	2,000	1,751	1,676	1,053	1,471	1,084	1,744	1,193	1,349	6,988	2,137	2,447	1,612	1,286	926	1,108	1,151	582	794	419	565	468	-	-	-
Depreciation And Amortization	632	331	131	130	158	147	126	155	145	156	164	171	26	246	247	341	286	460	428	428	423	406	475	474	473	468	440	280	234	219	200	210	202	176	157	-	-	-	-	-	-	-
Discontinued Operations	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-
Ebit	-4,270	-2,949	-4,593	-2,827	-1,934	-1,246	-3,644	-3,950	2,475	-11,729	-2,482	-2,653	294	-2,959	-6,430	-4,001	-6,838	-7,818	-7,738	-8,592	-6,319	-5,353	-8,210	-5,580	-8,470	-5,731	-3,645	-4,642	-5,181	-5,642	-4,112	-20,153	12,027	56,131	-81,339	-6	-1	-23	-4	-2	-	-
Ebitda	-3,638	-2,618	-4,462	-2,697	-1,776	-1,099	-3,518	-3,795	2,620	-11,573	-2,318	-2,482	320	-2,713	-6,183	-3,660	-6,552	-7,358	-7,310	-8,164	-5,896	-4,947	-7,735	-5,106	-7,997	-5,263	-3,205	-4,362	-4,947	-5,423	-3,912	-19,943	12,229	56,307	-81,182	-6	-1	-4	-4	-2	-1	-5
Effect Of Accounting Charges	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-
Extraordinary Items	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-
Gross Profit	1,686	1,641	1,209	2,415	1,807	1,292	1,235	1,361	1,813	1,259	637	1,855	1,750	1,560	1,599	1,490	1,083	967	767	777	544	396	352	843	403	203	1,498	-194	468	502	403	554	480	46	479	0	0	0	0	-	-	-
Income Before Tax	-4,304	-2,978	-4,620	-2,863	-1,958	-1,273	-3,670	-3,976	2,452	-11,767	-2,534	-2,721	206	-3,066	-6,551	-4,132	-6,983	-7,978	-7,901	-8,978	-6,335	-5,507	-8,302	-5,576	-8,478	-5,765	-3,651	-4,645	-5,185	-5,645	-4,115	-20,155	12,024	56,127	-81,765	-6	-1	-4	-4	-2	-1	-5
Income Tax Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	132	0	0	0	0	0	0	0	-	-	-
Interest Expense	34	29	27	36	24	27	26	26	23	38	52	68	88	107	121	131	145	160	163	386	16	154	92	4	8	34	6	3	4	3	3	2	2	4	427	0	170	674	639	-	0	0
Interest Income	-	-	-	-	-	-	-	-	-	-	2,467	263	4,342	2,630	1,243	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Minority Interest	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-
Net Income	-4,304	-2,978	-4,620	-2,863	-1,958	-1,273	-3,670	-3,976	2,452	-11,767	-2,534	-2,721	206	-3,066	-6,551	-4,132	-6,983	-7,978	-7,901	-8,978	-6,335	-5,507	-8,302	-5,576	-8,478	-5,765	-3,651	-4,645	-5,185	-5,645	-4,115	-20,155	12,024	56,127	-81,765	-6	-1	-4	-4	-2	-1	-5
Net Income Applicable To Common Shares	-4,304	-2,978	-4,620	-2,863	-1,958	-1,273	-3,670	-3,976	2,452	-11,767	-2,534	-2,721	206	-3,066	-6,551	-4,132	-6,983	-7,978	-7,901	35,410	-6,335	-5,507	-8,302	-33,815	-11,494	-9,970	-6,775	-24,245	-5,185	0	0	-45,793	12,024	56,127	-81,765	-6	0	0	0	-	-	-
Net Income From Continuing Ops	-4,304	-2,978	-4,620	-2,863	-1,958	-1,273	-3,670	-3,976	2,452	-11,767	-2,534	-2,721	206	-3,066	-6,551	-4,132	-6,983	-7,978	-7,901	35,410	-6,335	-5,507	-8,302	-23,470	-8,478	-5,765	-3,651	-19,590	-5,185	0	0	-33,769	12,024	0	-81,765	-6	0	0	0	-	-	-
Net Interest Income	-34	-29	-27	-36	-24	-27	-26	-26	-23	-367	-52	-458	-88	-813	-121	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non Operating Income Net Other	-	-	-	-	-	2,075	-531	-840	4,873	-8,675	2,247	-	-	-	-1,639	-	-889	-793	712	-	731	2,952	-161	-	-1,612	1,631	2,991	-	-4	-	-	-	15,756	-	-77,873	-	-	-	-	-	-	-
Non Recurring	-	-	-	-	-	-	-	-	189	244	-	-	-	-	-	0	0	0	0	-2,660	5,979	665	665	659	0	0	0	659	0	0	0	0	0	0	0	0	0	0	0	-	-	-
Operating Income	-3,654	-3,229	-4,237	-4,552	-2,789	-3,348	-3,139	-2,997	-2,421	-3,092	-4,781	-2,839	-3,790	-5,098	-4,912	-5,139	-6,094	-7,185	-8,613	-7,946	-7,066	-8,459	-8,141	-6,682	-6,866	-7,396	-6,642	-6,652	-5,181	-5,635	-4,093	-4,859	-3,732	-4,311	-3,892	-6	-1	-4	-4	-2	-1	-5
Other Items	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-
Other Operating Expenses	6,983	6,694	6,804	8,628	5,838	5,559	5,049	5,251	5,129	5,112	6,249	6,540	7,129	8,360	8,527	8,459	8,640	10,149	11,150	10,546	8,679	9,848	9,577	9,465	8,462	8,948	15,128	8,595	8,096	7,749	5,782	6,339	5,320	5,508	4,954	6	1	4	4	2	1	5
Preferred Stock And Other Adjustments	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3,016	4,205	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Reconciled Depreciation	170	331	131	130	158	147	126	155	145	156	164	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Research Development	936	920	999	818	618	709	603	712	599	452	711	564	1,149	1,499	1,384	1,368	1,282	1,389	1,808	1,992	1,986	2,632	2,873	2,293	2,216	2,221	2,149	2,042	1,713	1,742	983	1,304	1,096	699	769	512	453	790	922	-	-	-
Selling And Marketing Expenses	1,742	1,841	1,629	2,040	1,685	1,787	1,793	1,780	1,740	1,712	2,520	2,732	2,818	3,039	2,809	2,935	3,106	3,933	3,853	3,593	3,226	3,270	3,067	2,846	2,735	2,913	2,503	2,504	2,380	2,523	1,851	2,063	1,641	1,849	1,531	-	-	-	-	-	-	-
Selling General Administrative	2,662	2,109	2,818	4,109	2,293	2,144	1,978	1,866	1,706	1,943	2,187	1,379	1,593	2,120	2,317	2,350	2,785	2,827	3,738	3,285	2,414	2,475	2,553	2,582	2,318	2,465	3,488	1,912	1,556	1,872	1,662	2,046	1,474	1,809	2,071	2	1	3	3	2	-	-
Total Operating Expenses	5,340	4,870	5,446	6,967	4,596	4,640	4,374	4,358	4,045	4,107	5,418	4,675	5,560	6,658	6,510	6,653	7,173	8,149	9,399	8,870	7,626	8,377	8,493	7,721	7,269	7,599	8,140	6,458	5,649	6,137	4,496	5,414	4,212	4,357	4,371	6	1	4	4	2	1	5
Total Other Income Expense Net	-650	251	-383	1,689	831	2,075	-531	-979	4,873	-8,675	2,247	118	3,996	2,032	-1,639	1,007	-889	-793	712	-1,032	731	2,952	-161	1,106	-1,612	1,631	2,991	2,007	-4	-10	-22	-15,296	15,756	60,438	-77,873	0	0	1	0	0	0	0
Total Revenue	3,329	3,465	2,567	4,076	3,049	2,211	1,910	2,254	2,897	2,264	1,468	3,720	3,319	3,262	3,616	3,296	2,550	2,967	2,518	2,453	1,597	1,867	1,436	2,587	1,596	1,552	8,486	1,943	2,915	2,114	1,689	1,480	1,588	1,197	1,062	788	834	984	696	-	-	-

Latest Income Statement (annual, 2021-12-31)

Gross Profit (+$)
totalRevenue	11,246
Cost of Revenue	-4,497
Gross Profit	6,749	6,749

Operating Income (+$)
Gross Profit	6,749
Operating Expense	-20,577
Operating Income	-13,828	-13,828

Operating Expense (+$)
Research Development	2,748
Selling General Administrative	10,524
Selling And Marketing Expenses	7,305
Operating Expense	20,577	20,577

Net Interest Income (+$)
Interest Income	-
Interest Expense	-113
Net Interest Income	-113	-113

Pretax Income (+$)
Operating Income	-13,828
Net Interest Income	-113
Other Non-Operating Income Expenses	-
Income Before Tax (EBT)	-9,764	-17,892 EBIT - interestExpense = -9,764 -9,764 -9,651
Interest Expense	113
Earnings Before Interest and Taxes (ebit)	-9,651	-9,651
Earnings Before Interest and Taxes (ebitda)	-9,090

After tax Income (+$)
Income Before Tax	-9,764
Tax Provision	--
Net Income From Continuing Ops	-9,764	-9,764
Net Income	-9,764
Net Income Applicable To Common Shares	-9,764

Non-recurring Events
Discontinued Operations	-
Extraordinary Items	-
Effect of Accounting Charges	-
Other Items	-
Non Recurring	-
Other Operating Expenses	25,074
Total Other Income/Expenses Net	4,064	113